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Abstract 
 
The project aims focussed on three main areas of study; ischaemic injury assessment, 
laparoscopic renal cryopreservation and peritoneal cooling for non-heart-beating organ donation. 
The effects of renal ischaemia represent significant challenges for transplantation and urological 
surgery in that with sufficient unchecked ischaemic duration, permanent loss of function is 
inevitable. Prior to consideration of novel approaches to ischaemic protection, aimed at producing 
improved graft quality for transplantation and an increased safe operating times for partial renal 
resections, deficiencies in the literature regarding the efficacy of viability testing were targeted. 
Techniques of ischaemic injury assessment are intended to allow identification of retrieved kidneys 
which are likely to have lost the potential for adequate function if transplanted. Such organs can then 
be discarded, thus improving outcomes and decreasing rates of primary non-function. 
Results pertaining to ischaemic injury assessment provided support for protocols of viability 
assessment based on hypothermic machine perfusion. The effect of warm ischaemia on renal 
viability criteria has been successfully demonstrated in a large animal model, and novel approaches 
to the use of such assessments have been explored in order to maximise organ resource opportunities 
and utilisation. 
The project has made an important contribution in the technical approach to laparoscopic 
partial nephrectomy and laparoscopic renal hypothermia. The studies involving the ‘Newcastle 
Laparoscopic Renal Cooling Device’ succeeded in achieving ‘proof of concept’ with demonstration 
of effective renal cooling and preservation.. 
Studies relating to preservation interventions in the porcine model of the uncontrolled NHBD 
have produced striking results. These results strongly suggest that uncontrolled NHBD centres 
employing cold in-situ perfusion approaches to preservation would be wise to consider 
supplementary techniques of organ cooling. 
 
 
 
   3 
 
 
 
Aims   4 
Aims 
 
Ischaemic injury Assessment 
To assess the efficacy and potential of ischaemic injury assessment or viability testing within a renal 
Non Heart Beating Donor (NHBD) transplantation program by: 
a) Prospective assessment of the effects of warm ischaemia on retrospectively established measures 
of organ viability; machine perfusion and perfusate enzyme analysis in a large animal model. 
b) Assessment of outcomes of NHBD kidneys with low severity pre-arrest acute renal failure 
selected using machine perfusion viability testing  
c) Assessment of outcomes from dual renal transplantation of ‘marginal kidneys’ selected using 
machine perfusion viability testing 
 
Laparoscopic Renal Cryopreservation 
d) To develop a device for laparoscopic renal cooling 
e) To develop a large animal model for laparoscopic renal cooling 
f) To assess the efficacy of a laparoscopic renal cooling device using transplantation organ viability 
assessment 
 
Peritoneal Cooling 
g) To develop a large animal model of the uncontrolled NHBD for assessment of the efficacy of 
additional peritoneal cooling versus current protocols. 
h) To establish a human trial of uncontrolled NHBD peritoneal cooling. 
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Clinical Assessment of Renal Ischaemic Injury and the Role of Cryo-
preservation; Peritoneal Cooling in Non Heart Beating Donation and 
Topical Cooling for Laparoscopic Surgery 
 
 
 
Introduction 
 
 
1.1 History of renal transplantation 
 
Solid organ transplantation was first proposed by Alexis Carrel in 1902 in his paper La 
technique opérative des anastomoses vasculaires et la transplantation des viscères in 1902 (Carrel, 
1902). It was here that the now well-established technique of end-to end arterial anastomosis was 
first described. However in most other areas of transplantation medicine and surgery the field has 
changed significantly. 
By 1914 the surgical techniques necessary to perform renal transplantation had been 
developed in animal models (Carrel, 2001, Carrel, 1983). Vascular anastomosis to the iliac vessels 
was possible, with an aortic patch described for the arterial anastomosis. The outcome of renal 
transplantation in these animal trials was invariably acceptable initial function, followed by graft 
failure and death of the animal at seven to ten days. 
The first human kidney transplant was from a living donor. In 1936 in the Ukraine a surgeon 
named Voronoy performed a renal transplant from an unknown donor to a patient suffering acute 
renal failure secondary to mercury toxicity (Voronoy, 1936).  Both the donor and recipient died 
within seven days. 
After the initially disastrous attempts to treat end-stage renal failure (ESRF) with renal 
transplantation, in 1944 Kolff gave hope to sufferers with the invention of the dialyser (Kolff et al., 
1997), built in an enamel factory in occupied Holland. The advent of renal replacement therapy   13 
allowed clinicians the opportunity to manage uraemia. This extremely important, albeit imperfect, 
intervention continues to save lives to this day. 
The deficiencies of dialysis reinforced the notion that complete artificial replacement of 
normal human renal function was perhaps impossible. Further attempts at human kidney 
transplantation were made in Boston and Paris in the early 1950s, but the outcomes were 
depressingly similar to the animal trials of 1914.  Explanations for these failures came from Sir Peter 
Medawar, who postulated that the transplants had undergone ‘acute rejection by the immune system’ 
(Holman, 1924, Hume et al., 1952, Medawar, 1944, Medawar, 1945). He also showed that this 
process did not occur in transplants between genetically identical individuals. Renal transplants 
between identical twins were performed successfully from 1954 (Merrill et al., 1956, Murray et al., 
1958). 
The barrier to transplantation was broken when Sir Roy Calne pioneered the use of 6-
mercaptopurine(Calne, 1960), azathioprine (Calne and Murray, 1961) and later cyclosporine (Calne 
et al., 1978, Calne et al., 1979). The ability to prevent and treat acute rejection allowed renal 
transplantation to eclipse dialysis as the ultimate renal replacement therapy. Today no single 
procedure or intervention has been shown to increase patient quality of life (Parsons and Harris, 
1997), or be more cost-effective (de Wit et al., 1998) than a successful renal transplant for ESRF . 
 
1.2 The current situation in renal transplantation 
 
Renal transplantation in the UK is faced with enormous discrepancies between organ supply 
and demand. The traditional cadaveric, brain-stem dead, heart-beating donor source provides 
insufficient numbers of grafts for the ever-growing active waiting list. This situation is unlikely to 
reverse. In fact as existing renal grafts fail over time, and  the nephrotoxic effects of long term use of   14 
calcineurin-inhibitors (Gonwa et al., 2001, Klein et al., 2002) such as cyclosporine (Jankauskiene et 
al., 2001) and tacrolimus (Oka et al., 2001)  in recipients of other solid organs develop, things may 
yet get worse.  In addition the UK has experienced a significant fall in the numbers of transplants 
from brain-stem dead cadaveric donors performed annually (UKTSSA, 2003). This is thought to be 
secondary to improvements in road safety and therefore decreased mortality from road traffic 
accidents and intracranial haemorrhage (Briggs et al., 1997).  This appears to be a world-wide 
phenomenon, with similar patterns in many national registries (UNOS, 2000, Eurotransplant).  
Transplant clinicians have therefore sought out alternative donor sources, mainly through the 
development of living-related and unrelated donor programs. However initial data suggests the yield 
may be relatively low due to exclusions for unsuitability, legal and ethical constraints of unrelated 
donation, or because the donors change their mind (Saunders et al., 2000). 
 
 
1.3 Non-Heart-Beating Donor (NHBD) Transplantation 
   
1.3.1 History of NHBD transplantation 
Non-heart-beating donors (NHBD) represent the original renal transplantation donor group. 
Prior to the evolution of the concept of brain-stem death all organ donors were NHBDs. Evaluation 
of the results obtained in these very early transplants is of limited relevance to current practice due to 
the rapid evolution of medical and surgical organ transplant techniques. Equally, modern “state of 
the art” outcome data is presented elsewhere in this thesis. Rather, this section aims to chart the 
development and progress achieved in NHBD renal transplantation over the last two decades of the 
20
th century. 
The NHBD is not a single entity, as recognised by the First International Workshop on 
NHBDs held in Maastricht, Netherlands in 1995. Under the guidance of the chairman, Professor G.   15 
Kootstra, the original four Maastricht categories of NHBD were developed (Table 1.1). These were 
later amended to include a fifth category; essentially cardiac arrest and unsuccessful resuscitation in 
a hospital setting. It is immediately apparent that each category represents part of a wide spectrum of 
potential organ damage through ischaemic injury. In the early literature, prior to this useful sub-
division of the NHB donor group, identification of donor sub-type and therefore comparison of 
outcome data from different groups is fraught with difficulty.  
 
Table 1.1 
The First International Workshop on Non Heart Beating Donation;  
The Maastricht Categories of Non Heart Beating Donor 
 
Maastricht Category  Donor Situation 
I  Dead on arrival 
II  Unsuccessful resuscitation 
III  Awaiting cardiac arrest 
IV  Cardiac arrest in a brain-dead donor 
 
 
At this point, it is useful to introduce a broader dichotomy which exists within the NHBD 
group; a NHBD situation may be considered as controlled or uncontrolled. Controlled situations are 
generally expected and occur in hospital settings (categories III and IV), therefore time is available 
to organise personnel, equipment and undertake legal formalities prior to death. In this way, a well 
organised retrieval program allows procurement of good quality organs with a relatively short warm   16 
ischaemic time. With the uncontrolled donor (categories I and II) the situation is reversed; the donor 
comes from the community and the factors necessary for successful organ procurement must be 
mobilised and effected as quickly as possible. Uncontrolled donors are therefore associated with 
significantly longer primary warm ischaemic durations and therefore a greater propensity for 
ischaemic injury. The amended category V donor represents a mixture of the two donor situations 
and is relatively infrequently used.  
In the UK today a NHBD is generally assumed to be a category III donor, following 
withdrawal of treatment in an intensive care setting. Indeed the Newcastle-upon-Tyne group are 
currently the only UK unit actively retrieving kidneys from uncontrolled NHBDs. However this does 
not represent the situation found in early modern NHBD renal transplantation. This is because 
uncontrolled donor opportunities are, and were, far more numerous than those arising in controlled 
circumstances. As alluded to above, data presented in the eighties and early nineties from NHBD 
programs around the world describe the outcomes of transplants originating from varying mixtures 
of NHBD sub-groups. However, it is often possible to determine, or at least infer, the relative donor 
sub-group composition through close examination of the methods described. The majority of NHBD 
transplants during this period appear to have come from uncontrolled (mainly cat. II) situations. As 
shall be seen later, early NHBD procurement protocols and subsequent outcomes are predictably 
variable. 
The brain-stem dead patient currently represents the “ideal” donor situation where retrieval 
of high-quality organs is possible whilst maintaining a very short primary warm ischaemic time. A 
sharp transition from warm to cold ischaemia can then be achieved relatively easily using cold 
perfusion and the introduction of ice. Cryopreservation has formed the mainstay of organ ischaemic 
protection in modern renal transplantation due to early evidence of its effectiveness (Wickham et al.,   17 
1967) and its inherent simplicity. Recent research has demonstrated an increasing interest in more 
physiological, warm, oxygenated preservation techniques. However it is cryopreservation and the 
attempts to minimise warm ischaemic duration and sharpen the warm/cold ischaemic interface that 
have characterised the approach of the transplant community to NHB donation. 
As one reviews the literature, it is striking how little the introductions to papers related to 
NHBD renal transplantation have changed. Invariably, attention is drawn to a rising demand for 
organs coupled with a static or dwindling supply. The decline in conventional cadaveric (brain-stem 
dead) organ supply has been attributed to improved road and vehicle safety, and the success of 
living-related kidney donation programs have as yet proved unable to slake the waiting list’s thirst 
for kidneys. It is this consistent imbalance between supply and demand which has driven interest in 
marginal donor groups over the last twenty years, including and especially the NHBD. 
 
1.3.2 Early NHBD Renal Transplantation  
In 1975 Garcia-Rinaldi and Lefrak published details of a method of in-situ perfusion of 
cadaveric kidneys for transplantation (Garcia-Rinaldi et al., 1975). This paper introduced the 
concept of an aortic double-balloon triple-lumen (DBTL) catheter which could be placed via a 
femoral artery cut-down, in the early phase of the retrieval process. Once in place the two balloons 
are inflated (one above and one below the renal arteries), so isolating the renal circulation. Cold fluid 
can then be passed via the third lumen which exits the DBTL catheter through multiple holes 
between the two balloons (Figure 1.1).  
The time taken to get an uncontrolled NHBD to theatre for laparotomy and organ cooling can 
be relatively long, especially in countries such as the UK where an opt-in system requires prior 
completion of complex Coroner and family consents. During this period warm ischaemia continues   18 
to impact heavily on organ quality. The technical development of the DBTL catheter allowed 
transplant surgeons the opportunity to effect cryopreservation much earlier than had been previously 
possible. Therefore most successful early data from uncontrolled NHBD renal transplants used a 
form of early cannulation and in-situ cold perfusion during procurement. 
   19 
Figure 1.1 
In-Situ Cold Perfusion via Aortic placement of the Double-Balloon Triple-Lumen (DBTL) 
catheter. 
 
 
The DBTL catheter may be introduced via a femoral triangle cut-down procedure; marks on the 
catheter allow estimation of the length of catheter required to position the superior balloon above the 
celiac axis, and the inferior below the inferior mesenteric artery. Once inflated the splanchnic 
circulation is effectively isolated, and with venous venting, cold in-situ perfusion may be achieved     20 
1.3.2.1 The Japanese 
Brain-stem death was not legally recognised in Japan until relatively recently. As a result 
prior to this all cadaveric renal transplantation in Japan was performed using kidneys from NHBDs. 
The majority of donors would fit into the controlled Maastricht categories (III, IV and V), though 
systems were in place for rapid identification and response in the uncontrolled category II situation. 
As with most other countries (except more recently in Spain) category I donors were not used due to 
issues of unknown primary warm ischaemic duration. Modern programs could, and have, learned 
much from the Japanese approach to the NHBD as for many years they produced results comparable 
to western heart-beating donor (HBD) programs. An excellent illustration of this is found in the 1993 
publication from the Nagoya group (Yokoyama et al., 1993). This paper reported a ten-year 
experience of utilising the DBTL catheter in NHBD kidney procurement and transplantation. In 120 
renal transplants they reported a primary non-function (PNF) rate of 6.7% and a delayed graft-
function (DGF) rate of 68.3% with one-year graft survival rates of greater than 80% (the 
contemporary British Transplantation Society guidelines for HBD grafts). However, the excellent 
mean primary warm ischaemic time of 10.7 minutes suggests the majority of donors were well-
controlled and the questionably high DGF rate of 68.3% must be viewed in this context. 
 
1.3.2.2 The Europeans 
In Europe, the Maastricht group in the Netherlands led the way with their NHBD program 
based on DBTL catheterisation and in-situ perfusion (van der Vliet et al., 1980, van der Vliet et al., 
1981, Vromen et al., 1988). The Spanish also achieved relatively good results (Castelao et al., 1988), 
although overall rates of PNF were higher than is currently acceptable.   21 
In 1993 the Maastricht group called for a standardised protocol for in-situ preservation of 
NHBD kidneys in uncontrolled category II donors (Booster et al., 1993a, Booster et al., 1993b). The 
Maastricht approach centred on rapid local availability of DBTL cannulation and perfusion which 
was achieved by local surgeons who as junior surgeons had usually been trained on the transplant 
unit to perform the relatively simple technique of femoral cut-down and cannulation. This local 
expertise was later augmented with the addition of the “NHBD box” containing the necessary 
equipment and instructions to every Accident and Emergency department in the region. Strict donor 
criteria were employed to safeguard organ quality. Transplantation was contraindicated from donors 
with any of the following; age >60yrs, evidence of sepsis, history of intra-venous drug use, 
hypertension, diabetes mellitus, or cancer. The limit for the primary warm ischaemic time was set at 
30 minutes. 
In the 98 kidneys retrieved from 49 category II donors between 1980 and 1990, 70 were 
transplanted within the Netherlands, 16 in Maastricht. Follow-up data was only presented from the 
Maastricht transplants, compared to 30 well-matched HBD renal transplants. The PNF rate was 
significantly higher in the NHBD vs. the HBD groups (12.5% vs. 6.7%), as was DGF (75.0% vs. 
43.3%). More positively, the graft and patient survival were not significantly different between the 
groups. Functional outcomes, measured crudely by serum creatinine, also showed no significant 
differences with regard to NHBD vs. HBD status or immediate function vs. DGF.   
It is interesting to note that from 1980-1990 the Maastricht group reported a non-use or 
discard rate of 28.6%. They, and others, had begun to machine perfuse NHBD kidneys during the 
cold ischaemic phase in order to achieve better wash-out of blood, and better  delivery of 
preservation solution. This also produced pressure/flow data which might reflect the vascular injury 
sustained by the organ. Amongst the reported reasons for organ non-use is “poor machine perfusion   22 
parameters” which previews the organ viability testing debate to come. Also notable is that the in-
situ perfusion solution employed was histidine-tryptophan-ketoglutarate (HTK) which was later 
shown to be superior to the Euro-Collins solution commonly used at the time (de Boer et al., 1999). 
In the UK, several groups had commenced NHBD programs. In Newcastle-upon-Tyne a 
controlled category III program with rapid laparotomy, cannulation and cold perfusion achieved 
“success rates” (recipient alive and free from dialysis) of 90.5% at one year between 1988-1993 
(Balupuri et al., 2000c). However, Newcastle’s later experience with uncontrolled donors from 
1994-98 was not so positive, with an unacceptable PNF rate of 55.5%, resulting in temporary 
termination of the program. This will be discussed in more detail later.  In 1994 both the Leicester 
and Guy’s (London) groups reported high rates of PNF from their early experience. The Leicester 
group begun their NHBD program in 1992 and reported a PNF rate of 12% in the first year (16 cat II 
and III transplants) (Varty et al., 1994). The London group had started in 1988, aiming to retrieve 
kidneys from category II donors in the accident and emergency situation as well as from category III 
/ V patients with mainly intra-cranial tumours in hospice settings. In the 27 resulting transplants 
performed between 1988 and 1991, the PNF rate was 25.9% and the two year graft survival 55%. As 
a result older age and hospice patients were no longer considered for donation (Phillips et al., 1994). 
 
1.3.2.3 The United States of America 
NHBD renal transplantation was not prevalent in the USA during the eighties and nineties. 
However the Pittsburgh and Washington groups were producing interesting results. In early 1995 the 
Pittsburgh group reported their experience with a protocol based on rapid laparotomy, cannulation 
and cold perfusion (i.e. no DBTL in-situ perfusion prior to laparotomy). 24 NHBD retrievals (14 cat. 
II, 10 cat. III) were performed during 1989-93. In the category II transplants the PNF rate was 5%   23 
and DGF rate 64%, with a one year graft survival of 86%. In the category III transplants no PNF was 
observed with a one year graft survival of 82% (Casavilla et al., 1995). Importantly the Pittsburgh 
protocol included a post-retrieval biopsy which was examined prior to transplantation. 18.5% and 
15% of category II and III organs were discarded on the basis of the biopsy findings. This process is 
arguably analogous to the Maastricht viability testing using machine perfusion. In any case results 
certainly appeared superior to those produced in the UK where no formal assessment of organ 
quality was undertaken. 
With varying rates of success and failure in evidence across the world, the First International 
Workshop on NHBDs was convened in Maastricht, Netherlands. 
 
1.3.3 The First International Workshop on Non Heat Beating Donation;  
Maastricht, Netherlands 1995 
Chaired by Professor G Kootstra, the workshop covered the spectrum of issues concerning 
NHBD at the time. In many cases these issues remain relatively unchanged today. Topics included; 
the ethics of uncontrolled NHBD retrieval and invasive measures of organ preservation prior to 
consent, the role of reinstitution of CPR techniques after death, DBTL in-situ perfusion versus rapid 
laparotomy, and the potential role of viability testing using machine perfusion and perfusate enzyme 
data. 
In terms of results, several groups reported their experience to date. The Leicester group had 
reached the 3 year point in their category II program, and presented data from 1992-95 (Dunlop et 
al., 1995). Using donor exclusion criteria similar to the Maastricht group (Age <60 yrs etc.), DBTL 
in-situ cold perfusion with Coroner’s permission (prior to family consent for donation), often with 
the reinstitution of ventilation and cardiac massage with a ‘thumper’ device, Leicester retrieved 44   24 
kidneys. 30 were transplanted locally with a PNF rate of 10%, DGF 100%, and a one year graft 
survival of 93.3%. These creditable results, despite 100% DGF, were achieved without viability 
testing. However, they came at another cost, namely effort and resource. The Leicester group 
responded to 73 potential donors during the study period from which only 24 actually proceeded to 
retrieval. 
In Maastricht, Kootstra’s uncontrolled NHBD work had continued apace. In the two years 
since their last group data publication, they increased the number of locally transplanted kidneys 
from 16 to 57 (Wijnen et al., 1995). From these transplants (1980-1992), with a mean follow-up of 
85 months, data was presented at 1, 3, and 5 years post implantation compared with a matched group 
of 60 local HBD transplants. PNF rates were <3% in both study groups, though the DGF rate was 
predictably significantly higher in the uncontrolled NHBDs (60% vs. 35%). No significant 
differences were seen regarding graft survival or functional outcome. 
The Madrid group were also producing strong results, but in category III donors. The 
protocol at the time involved perfusion with Euro-Collins via a central venous line at cardiac arrest, 
followed by rapid transfer to theatre, laparotomy, cannulation and cold perfusion. 52 NHBD 
transplants were compared to 98 HBD. No significant differences in PNF or nine-year graft survival 
were observed. DGF (67% vs. 46%) and serum creatinine at 1 year were higher in NHBDs, but this 
difference became non-significant by 5 years (Gonzalez Segura et al., 1995). 
This was clearly extremely encouraging data, but difficult to reconcile with contrastingly 
poor results elsewhere. In reply to the Lancet paper by Wijnen described above, Rene Chang from 
London highlighted what he felt to be an “over-optimistic gloss” regarding the potential results that 
could be achieved using NHBDs (Chang, 1996, Andrews et al., 2001). He based this assertion on the 
results of his local uncontrolled program, reiterating the group’s early results as described above.   25 
The Maastricht group may well have pointed out that although their results had improved, their 
organ non-use rate had increased from 28.6% to 34%. The reason for this was the Maastricht 
viability testing protocols, soon to be published, which had the potential to select out retrieved 
organs which were likely to result in PNF. Although we can assume thorough subjective assessments 
are likely to have occurred in other centres, arguably it was the objective, formalised, quantitative 
assessment which produced the impressively low rates of PNF seen in Maastricht, albeit at the cost 
of an expensive non-use rate. 
 
1.3.4 Into the Modern Era of NHBD Renal Transplantation 
In the UK by 1998, the London group had ceased retrievals from uncontrolled NHBDs and 
Leicester were possibly having doubts. In their HBD comparison paper of 1997, the Leicester group 
examined 30 category II and III transplants against 114 HBD. Against the HBD group, the DBTL in-
situ cold citrate perfusion NHBD protocol, with a 40 minute primary warm ischaemic cut-off, 
produced a PNF rate of 13% (mainly in uncontrolled donors) and an inferior serum creatinine at 2 
years (Butterworth et al., 1997, Nicholson et al., 1997). More telling is the Elwell paper of the same 
year concerning the outcome of Leicester NHBD referrals (Elwell et al., 1997). From 144 NHBD 
referrals made between 1992 and 1997, there were only 48 resulting retrievals. The group bemoaned 
the waste of time, effort, and resource, which must have been extremely frustrating. Leicester later 
published some excellent uncontrolled results (PNF 7%, 8 year-graft survival better than HBD) 
(Metcalfe et al., 2001), demonstrating a learning curve and possibly an experienced leadership with 
an eye for which kidneys and/or donor situations were likely to end in PNF. However, the Leicester 
uncontrolled NHBD program was later terminated.   26 
Elsewhere many groups continued to produce good results using both controlled and 
uncontrolled NHBDs (Pokorny et al., 1997, Tanabe et al., 1998). Possibly the most impressive 
uncontrolled NHBD data to date was produced in the USA by Dr Light’s Washington group. In 1994 
they established a rapid organ recovery program (RORP) for NHBDs. The protocol involved DBTL 
in-situ cold perfusion and hypothermic machine perfusion following retrieval (similar to the 
Maastricht protocol). However the Washington group were the first to use additional peritoneal 
cooling, via two abdominal trocars, one for inflow and one outflow of iced saline (Light et al., 
1997). Initial data (1994 and 1997) reported retrieval of 29 kidneys of which 23 were transplanted. 5 
kidneys functioned immediately, 16 after a period of delayed graft function and 2 experienced PNF. 
From donor 22 onwards the Washington method was refined by use of a peritoneal cooling 
circuit involving a heat-exchange coil in a sub-zero ice/alcohol fluid bath. Improved intra-peritoneal 
temperatures were subsequently achieved (10°C after 8 minutes cooling). Excellent clinical results 
were observed. No further PNF was seen and the DGF rate fell from 71% to 50% (Light et al., 
2000a). From a critical stand-point however, the Washington donors were mainly young trauma 
(gun-shot) victims and therefore the results obtained have limited validity for older, often co-morbid 
European donor groups. 
 
1.3.5 The Advent of Renal NHBD Viability Testing 
By the early 2000’s a dichotomy in NHBD practice had formed in Europe. Groups could be divided 
into those retrieving from controlled NHBDs without viability testing protocols, and those retrieving 
from both controlled and uncontrolled NHBDs with machine perfusion viability testing. The 
Maastricht group had published widely regarding their methods of identification of damaged organs 
(Daemen et al., 1997b, Daemen et al., 1997c, Kievit et al., 1997). These viability criteria were based   27 
on impaired flow and high resistance during machine perfusion, and measurement of enzymatic 
markers of ischaemic injury. The main marker chosen was alpha glutathione-s-transferase (GST), 
released by damaged proximal tubular cells and washed-out into the perfusate. 
Newcastle-upon-Tyne had experienced disastrous uncontrolled PNF rates between 1994 and 
1997, which resulted in the termination of the program. During this period no machine perfusion or 
viability testing protocols had been employed. From 1998 the uncontrolled program was reinstituted 
(phase III) using a modified Maastricht protocol of DBTL in-situ perfusion and a locally produced 
machine perfusion device. Viability testing was performed using pressure / flow characteristics and 
perfusate GST.  Early data from phase III was vastly improved. From 11 uncontrolled retrievals, 7 
kidneys were discarded on the basis of viability testing and 15 renal transplants were performed. The 
PNF rate was 1/15 (6.7%), with a 92% “success rate” (patient alive and free from dialysis) at one 
year (Balupuri et al., 2000c, Balupuri et al., 2000b, Balupuri et al., 2000a). By 2002, 88 NHBD 
transplants had been performed (cat. II 56%, cat. III 39%, cat. IV 5%) and were compared to a well-
matched group consisting of the next consecutive local HBD transplant. The kidney non-use rate 
was high at 47.7%, but in return no significant differences were observed with respect to PNF, 3 year 
graft / patient survival, or 3 year eGFR (estimated glomerular filtration rate) functional outcomes 
(Gok et al., 2002b). 
With the Maastricht and Newcastle evidence mounting, many felt the case for machine 
perfusion and viability testing in NHBD kidneys was well-made. Indeed, writing in the Lancet, Yves 
Vanrenterghem of the Leuven group stated that;  
“The development of a non-heart-beating program is no longer acceptable if machine perfusion and 
viability testing are not available”(Vanrenterghem, 2000).   28 
This was an understandably troublesome statement for groups successfully transplanting controlled 
NHBD kidneys with simple static cold storage. Letters sent to the editor of the Lancet included 
responses from the Leicester and Guy’s groups. The Leicester group (Metcalfe and Nicholson, 2000) 
argued that the reduction in PNF seen in the Newcastle data could be analogous to the reduction seen 
during the first and second  halves of the Leicester program. They attributed this to the “learning 
curve” phenomenon, which undoubtedly plays an important role in the evolution of any NHBD 
program. With experience (and likely previous bad experiences with PNF) program leaders become 
more discerning regarding which organs they are prepared to transplant. This itself may amount to a 
form of subjective “viability testing” in the following way. An experienced NHBD surgeon will 
collate information regarding ischaemic duration, donor demographics, quality of perfusion, 
macroscopic appearance etc. and come to a conclusion regarding the probability of a successful 
outcome. The development of such individuals within a program will result in improved outcomes. 
However problems may arise when such people leave or are unavailable. Also, the Leicester group 
pointed out that the cautious subjective approach may result in a high non-use rate (1.4 transplanted 
kidneys per retrieval in Newcastle vs. 0.5 in Leicester) and welcomed a reliable objective test. 
The Guy’s group also contested Yves Vanrenterghem’s statement (Gerstenkorn et al., 2000). 
They argued that only half the discarded organs had been excluded on the basis of viability tests 
alone, and that the Maastricht / Newcastle tests were unvalidated as it could not be proven that the 
discarded organs would not have functioned. In conclusion they sensibly suggested that current 
NHBD programs should continue if, as per British Transplantation Society guidelines, the one year 
graft survival was ≥80%.   29 
If Yves Vanrenterghem’s statement had read; “The development of an uncontrolled non-heart-
beating program is no longer acceptable if machine perfusion and viability testing are not available” 
it is likely that few would have argued. 
Success in NHBD renal transplantation is defined by low rates of PNF, and rates of graft 
survival and function comparable to those of HBDs. DGF is a very common, if not routinely 
expected, complication of NHBD kidney transplantation. However, medium-term evidence suggests 
that following recovery, DGF grafts will go on to perform comparably with non-DGF grafts (Light 
et al., 2000b). 
Explanations for poor outcomes can be attributed to two main areas. These are excessive ischaemic 
injury (which can be due to long primary WIT cut-offs or ineffective preservation interventions), and 
failure to identify damaged organs which should not be transplanted (lack of effective viability 
testing). In the controlled NHBD situation poor outcomes can be avoided with proper attention to 
effective retrieval techniques. As primary warm ischaemic times (WITs) are short, it is possible to 
run successful programs without formal viability testing. In the uncontrolled situation, where 
primary WITs are much longer, effective cryopreservation interventions and viability testing are 
essential. In this way, through the identification and non-use of excessively damaged organs, the 
PNF rate is kept to acceptable levels. 
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1.4 Ischaemic Injury in NHBDs 
   
 
For the reasons outlined earlier, transplantation clinicians fear the high PNF and DGF rates 
previously associated with NHBD grafts (Balupuri et al., 2000c). The pathophysiological processes 
producing these unwelcome clinical syndromes are, in the main, acute tubular necrosis (ATN) and 
vascular injury secondary to warm ischaemia. The severity of the damage sustained determines 
whether a transplant will result in immediate function, DGF, or PNF. 
If post-transplantation DGF occurs, the recipient will require dialysis until the graft is 
functioning, and for this he must remain in hospital.  Both dialysis and increased hospital stay is 
expensive, and patients with DGF can suffer significant psychological morbidity. The consequences 
of PNF are clearly unacceptable. Therefore the most important interventions in any NHBD situation 
act to prevent or limit the effects of warm ischaemia. 
In many NHBDs cardiac arrest may be preceded by a period of hypoxaemia and inadequate 
organ perfusion secondary to the pathological processes causing death. In this way ischaemic injury 
may begin prior to the point that renal oxygen delivery ceases completely and the warm ischaemic 
period officially begins.  At arrest the kidney is at normal temperature and hence renal cells remain 
metabolically active and continue to use ATP.  Without oxygen and aerobic respiratory substrate 
delivery, intracellular ATP concentrations begin to fall. This stimulates the enzyme 
phosphofructokinase, causing a shift to anaerobic metabolism of glucose which produces ATP, if 
only in much reduced quantities. In the context of anaerobic respiration, toxic metabolites 
accumulate and result in intracellular acidosis and functional enzyme inhibition (Trump, 1982). 
If the cells remain warm, ATP levels will continue to fall. Without sufficient availability of 
ATP the Na
+/K
+-ATPase transporters in the cell membrane cease to function, leading to a cellular   31 
influx of sodium and efflux of potassium along concentration gradients. Ca
2+/Mg
2+-ATPase 
dysfunction results in vastly raised intracellular calcium and decreased magnesium levels. Mg
2+ is 
important for enzyme function, and deficiency leads to mitochondrial failure and impairment of 
membrane repair mechanisms. Calcium ions entering the cell with greatly increased intracellular Na
+ 
concentrations result in osmotic cell swelling, loss of plasma membrane integrity and ultimately cell 
death (Trump, 1982). 
Once ATP is exhausted, energy may be released from the conversion of ADP to AMP, and 
subsequently from the conversion of AMP to adenosine. Adenosine is not conserved within the cell 
and hence if this state is reached, the possibility of ATP regeneration on reperfusion is much 
reduced.  When cells die toxic free radicals and lysosomal enzymes are released damaging nearby 
cells adjacent cells and contributing to tissue necrosis. 
Human metabolic rate will halve with every 10°C reduction in temperature (Wickham et al., 
1967). Thus by reducing organ temperature from 37°C to 7°C the metabolic rate, and thus ATP 
consumption, can be reduced by 87.5%. This is a major aim of the cold in-situ perfusion techniques 
discussed below. In addition, perfusion preservation solutions contain similar electrolyte 
concentrations to intracellular fluid, in order to limit the effects described above if ATPase 
transporters fail.  Some perfusion fluids go further still, with the inclusion of adenosine to limit 
cellular loss, glucose as a metabolic substrate, free radical scavengers, and colloids to reduce tissue 
oedema. 
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1.5 Assessment of Renal Ischaemic Injury 
1.5.1Why Assess Injury? 
NHBD kidneys have invariably sustained a degree of warm and cold ischaemic injury, with 
the most extreme cases seen in uncontrolled donor situations. Renal injury can be considered as a 
spectrum, ranging from mild reversible damage, to irreversible injury such that an organ will never 
regain function. The presence of certain factors (e.g. short ischaemic times, young healthy donor, 
and effective cryopreservation) will reliably suggest minimal injury and the potential for a good 
transplantation outcome. Equally, experienced personnel might become very good at predicting 
likely organ quality, hence avoiding PNF. It could be argued that such factors are essentially 
subjective viability assessments. However, in uncontrolled donors subjective assessments are too 
weak to allow confident practice. Objective methods of assessing ischaemic injury and viability must 
be sought. 
 
1.5.2 Machine Perfusion Viability Assessment in Kidneys 
The aim of machine perfusion is to improve upon static cold storage of donor organs through 
improved delivery of cold preservation solution and better wash-out of donor blood. In this way, 
more cells are more rapidly exposed to the beneficial cooling and metabolic effects of the 
preservation solution, and immunogenic factors within the donor blood are removed. In NHBDs the 
parameters involved in hypothermic machine perfusion can also be used as indicators of organ injury 
and hence viability. Such techniques follow from Kootstra’s research into methods of preservation in 
the 1980’s and 1990’s (Booster et al., 1993b, Daemen et al., 1995, Kootstra, 1988). The machine 
perfusion system he used was principally the Gambro® machine which was modified by using steel 
containers with glass lids, into which the kidneys were placed. The perfusion system re-circulated a   33 
University of Wisconsin solution® with supplementary oxygen delivery but without using an 
oxygen carrier compound. Some centres, including Newcastle-upon-Tyne used locally built systems. 
In the United States, later development produced the Waters® machine and later the Organ 
Recovery systems Inc. LifePort® kidney transporter. The Lifeport® is now commonly used 
throughout Europe and the US, and has been used in Newcastle-upon-Tyne since 2003.  
 
1.5.3 Parameters for NHBD Kidney Viability Testing in Newcastle-upon-Tyne 
1.5.3.1 Early Problems 
Hypothermic machine perfusion was introduced into the Newcastle NHBD protocol in phase 
III of the program in 1998.  The consensus view at the time was that the required flow rate was in the 
region of 0.5ml
-1 gram of kidney
-1 minute
-1 It was also thought that a safe maximum for perfusion 
pressure was 60mmHg (Balupuri et al., 2000b, Balupuri et al., 2000c). A locally-constructed system 
was initially employed, based on a haemodialysis pump (capable of delivering a much higher 
pressure than 60mmHg). It was found that achieving the desired flow rate in marginal NHBD 
kidneys was often difficult. Subsequently, it became common practice to increase the perfusion 
pressure to >60mmHg, especially in the early phase, in order to ‘open up’ the renal vasculature. 
Clearly this contravened the consensus regarding maximal pressure (Grundmann et al., 1975). In 
addition, it had been shown that maximal resistance to flow was expected at the beginning of 
machine perfusion, and that it would fall significantly during the first hour. This fall in resistance 
was assumed to represent the absence of intra-vascular thrombosis, and was cited as an indicator of 
organ viability (Talbot et al., 2003). However, a resistive drop may be seen in organs with both very 
good and very poor initial flows. It was also possible to unintentionally make a highly damaged 
kidney appear less damaged by using an excessive perfusion pressure. The process responsible   34 
involved the opening of arterio-venous shunts (Last, 1978 p.319) which caused a drop in resistance. 
Also, with the advent of perfusate enzyme measurement these arterio-venous shunts assumed further 
importance as they effectively cause ‘bypassing’ of the renal cortex. Thus the enzymatic markers of 
ischaemia, released by damaged tubular cells, are not encountered and washed out into the perfusate. 
The levels measured in the effluent would therefore appear much lower than if the cortex of the 
kidney had been perfused (Talbot et al., 2003). Again, a highly damaged organ may appear less 
damaged. Another effect of excessive perfusion pressure is excessive organ weight gain. This 
phenomenon is seen where fluid is forced out into the interstitium by hydrostatic pressure. As such, 
it was seen equally frequently in less damaged kidneys, and was exacerbated by the low oncotic 
pressures associated with early (starch-free) solutions. 
 
1.5.3.2 The Newcastle-upon-Tyne Pressure Flow Index (PFI) 
In an effort to overcome these issues, the Newcastle group devised an index which 
incorporated factors of systolic pressure as well as pure flow or resistance. This was termed the 
Pressure Flow Index (PFI), and was calculated from the flow per 100g renal mass divided by the 
systolic pressure of machine perfusion (ml
-1 min
-1 100g
-1 mmHg
-1). Retrospective analysis of 
machine perfusion and dichotomous (successful/unsuccessful) outcome data, identified a PFI 
viability threshold of 0.4 ml
-1 min
-1 100g
-1 mmHg
-1 (Balupuri et al., 2000b). The maximum pressure 
utilised for machine perfusion was reduced to 40 then 30mmHg. By using pressure as a denominator 
operators were less likely to increase perfusion pressures in order to achieve minimum requirements 
set for flow rate; a practice which had the potential to cause injury. Furthermore, with the change 
from the locally-constructed device to the Organ Recovery Systems Lifeport® machine such 
practices were no longer possible as the Lifeport limits perfusion pressures.    35 
 
1.5.3.3 Perfusate Analysis for Renal Viability Assessment 
An ideal viability marker for renal NHBD transplantation could be defined as an easily 
measurable, accurate indicator of ischaemic injury irreversibility. Physiological markers of 
ischaemia commonly used clinically have disadvantages in this context; pH is affected by 
physiological and perfusion fluid buffering systems and is hence of limited value. Perfusate lactate 
levels may indicate the degree of cellular acidosis but do not denote reversibility i.e. the potential for 
recovery. This has led transplantation clinicians to examine the release of certain intracellular 
enzymes into the effluent. Intra-cellular enzymes should only be released following membrane 
disruption, when a cell dies. They should therefore confer an indication of irreversible injury. 
 
1.5.3.4 Glutathione-S-Transferase (GST) 
GST (or ligandin) was originally isolated as an abundant intracellular enzyme in the proximal 
tubules of Sprague Dawley rats. Subsequently, GST has been found to be present in various cell 
types; liver, heart, ovary, testes, small intestine and adrenal. Isometric differences exist between cell 
types. In the kidney GST isomers are involved in detoxification via conjugation reactions. Proximal 
tubular cells express predominantly α-GST and hence this is the isomer released following injury. 
Distal tubular cells express π-GST which therefore can be measured in urine. That said, various 
isomers may be released from both renal cell types and as the machine perfusion system only 
involves one organ it could be argued that determining isometric levels of the enzymes is 
unnecessary. The total GST enzyme level is sufficient for the purposes of assessment of viability for 
a single kidney in a circuit. Total GST levels can be determined by a relatively simple 
spectrophotometric assay. This assay is described in detail within the methods chapter. It is based   36 
upon the rate of change of photon absorbance occurring at 340nm when the substrate 1-chloro-2, 4-
dinitrobenzene is conjugated with glutathione (Habig and Jakoby, 1981).  
GST has been used to assess injury in NHBD kidneys for some time. Daemen et al  
established a viability threshold perfusate level of 200 IU/L by retrospective analysis of outcome 
data (Daemen et al., 1997a), based on a perfusate circuit volume of 0.5L. This upper limit was 
adopted in Newcastle (Balupuri et al., 2000d), although it was noted that levels above 200IU were 
more commonly seen in young donors (presumably with more nephrons per kidney). In such 
situations, where other factors in the donation were considered favourable, some discretion regarding 
marginal breaches of the 200IU threshold were employed. Following introduction of the Lifeport 
system in Newcastle, the circuit volume required was increased to 1L. The GST viability threshold 
was therefore also altered, and has been set at 100IU/L since 2003. The current criteria used for 
viability testing in Newcastle are summarised in Table 1.2.   37 
Table 1.2 
Newcastle-Upon-Tyne NHBD Machine Perfusion Viability Parameters 
Perfusion pressure (mmHg)   < 30 mmHg 
 
Flow   > 12ml/100g 
 
PFI (ml/min/100g/mmHg)   >0.4 
 
Temperature (°C)   < 12˚C (surface temperature) 
(five time points) 
 
GST   ≤ 100 IU/100g 
 
Wt increase (%)   < 25 % (relative contraindication) 
 
Perfusion fluid  
Machine Perfusion Solution 
KPS (Belzer II, Belzer MPS) 
 
Donor pre-treatment   Heparin and Streptokinase 
 
 
 
1.5.4 Problems with Viability Testing 
For a viability assessment protocol to be deemed 100% successful, the program PNF rate 
would necessarily be 0%. This is a utopian aim and in reality, when dealing with marginal donor 
situations, viability assessment can be judged a success if PNF rates are maintained below the 
accepted limit of 10% (BTS guidelines 2008). In Newcastle, the use of PFI and GST-based tests 
have been reasonably successful at identifying heavily damaged NHBD organs and hence PNF 
levels have been uniformly kept below the 10% yearly limit (Gok et al., 2002a, Gok et al., 2004a). 
However, as above, every case of PNF represents a failure of viability assessment. 
  Deficiencies associated with the markers used in the Newcastle protocol are likely to 
represent deficiencies in our understanding of the extreme complexity of ischaemia reperfusion   38 
injury and the transplantation process. It is also likely that any viability assessment protocol capable 
of 100% sensitivity would suffer significantly in terms of specificity. In other words, the non-use 
rate would be very high. Organ non-use is extremely resource expensive and damaging to NHBD 
programs.  
  Ethics determine that the PFI and GST viability protocol in Newcastle must remain 
unvalidated. However if the effects of increasing ischaemic duration on PFI and GST could be 
demonstrated prospectively, the case for such assessment would be strengthened. The efficacy of 
current protocols in the determination of transition between states of reversible and irreversible 
injury should also be examined. Lastly, given the program-damaging effects of organ non-use 
further consideration should be given to the fate of organs on the borderlines of viability. If such 
organs could be used, possibly through improved preservation or by novel transplantation 
techniques, organ resources could be maximised. 
 
1.6 Renal Cryopreservation 
In his famous ‘Regional Renal Hypothermia’ paper of 1967, Wickham reviewed evidence 
from human and mammalian histological, physiological and transplantation studies in order to better 
elucidate the tolerated period of renal ischaemia (Wickham et al., 1967). He suggested that to avoid 
permanent loss of renal function any warm ischaemic period should not exceed 30 minutes. To avoid 
even minimum depression of function renal ischaemia should not exceed 10 minutes.  
Cooling of an organ results in decreased metabolic requirements and hence ischaemic 
protection. Wickham went on to describe his own renal cooling experiments with rabbits in relation 
to the body of the literature available at the time. Levy and Semb’s O2 consumption studies (Semb, 
1959a; Semb, 1959b) had shown almost full suspension of renal metabolic activity at 15-20
oC, and   39 
Bickford had shown complete suspension of tubular transport function at 17
oC (Bickford and 
Winton, 1937). Wickham himself showed that in rabbits, kidneys cooled to 20
oC could sustain up to 
three hours of renal ischaemia without appreciable deterioration in renal function, as measured by 
serum creatinine, or development of histological evidence of damage. The conclusions were that to 
achieve short-term hypothermic functional preservation with human kidneys, moderate parenchymal 
cooling to temperatures of approximately 15-25
oC is required. 
 
1.6.1 Cryopreservation in Urological Surgery 
The field of renal cryopreservation also has clinical applications outside of organ 
transplantation. The second major area of interest is that of urological surgery, in particular the 
procedure of partial nephrectomy, where it is necessary to subject kidneys to an ischaemic period, 
prior to reperfusion. 
The surgical management of renal cell carcinoma has traditionally meant patients proceeding 
to radical nephrectomy. This leads to approximately 50% reduction in nephron mass and 
consequently a similar loss of renal function to the patient. However partial nephrectomy is now 
considered a safe alternative for small localised renal cell tumours (Fergany et al., 2000, Gilbert et 
al., 2003). Due to the nephron-sparing capacity of the procedure, partial nephrectomy is considered 
the preferred form of treatment for T1a tumours (<4cm) in patients with small or solitary kidneys 
(Adkins et al., 2003, Ghavamian et al., 2002) and those with small bilateral tumours (Bernardo and 
Gill, 2002). 
The role of laparoscopic radical nephrectomy for management of T1-2 renal cell carcinoma 
is universally accepted (Abbou et al., 1999). However, laparoscopic partial nephrectomy (LPN) has 
been slow to gain universal acceptance, despite data suggesting that LPN can produce equivalent   40 
outcomes to open partial nephrectomy (El-Ghoneimi et al., 2003, Gill et al., 2003b). LPN follows 
the same principles as the open procedure; the renal blood supply is occluded by soft clamping of the 
renal vasculature prior to incision. Renal blood flow can then be re-established once the tumour has 
been excised and the edges are closed. During this period, the remaining kidney mass is exposed to 
the effects of warm ischaemic injury. It is difficult for a surgeon, especially whilst learning the 
procedure, to complete LPN within the prescribed 30 minute safe period (Wickham et al., 1967).  
Therefore where a urological surgeon anticipates the necessity of a significant period of renal 
ischaemia, there is a need to ensure renal hypothermia, in order to afford the organ sufficient 
ischaemic protection.   
During open partial nephrectomy, topical cooling is applied to the relevant kidney during 
renal pedicle clamping, usually via the introduction of ice slush to the region. Similarly in 
laparoscopic renal surgery attempts have been made to reduce the warm ischaemic damage 
occurring during renal pedicle clamping by use of a cooling jacket (Herrell et al., 1998), placement 
of ice slush (Ames et al., 2005, Gill et al., 2003a, Laven et al., 2007), irrigation with cold fluid 
(Webster et al., 2005, Weld et al., 2007), intra-arterial cold perfusion (Janetschek et al., 2004), and 
by retrograde ureteral perfusion of the kidney with cold saline (Crain et al., 2004, Landman et al., 
2003).  
Vascular cooling can be achieved through trans-arterial cold perfusion and effective 
performance has been reported using this approach (Janetschek et al., 2004). Despite this, many 
surgeons would prefer alternative techniques due to the unavoidable risks of vascular injury and 
thrombosis, as well as issues of technical complexity.   41 
Ureteral cooling is undertaken by retrograde perfusion with cold saline via a ureteral access 
sheath. This method requires post-operative stenting, and provides less effective cortical cooling 
than surface techniques (Crain et al., 2004, Landman et al., 2003). 
Surface cooling may be achieved in a number of ways; Herrel et al described a renal cooling 
device consisting of a rectangular double-layered plastic envelope through which cold fluid was 
circulated. The kidney to be cooled was placed into the envelope via an open side. Data was 
presented from cooling trials in four pigs. In 3 pigs the device was deployed via an open incision, 
and in one via an 18mm laparoscopic port. This limits assessment of the manoeuvrability and ease of 
application of the Herrel device in a purely laparoscopic setting. The Herrel device was not 
developed further.   
More recently, techniques involving placement of ice slush in close proximity to the kidney 
have been employed and demonstrate effective renal cooling (Ames et al., 2005, Gill et al., 2003a, 
Laven et al., 2007). However, critics point to the potential for whole body cooling and the limitation 
of access. Also, techniques involving direct application of coolant have the potential for causing 
injury through tissue freezing. Irrigation/suction systems using chilled normal saline (Webster et al., 
2005, Weld et al., 2007) avoid access and freezing issues, but remain subject to issues of potential 
contamination and core temperature reduction. A device which could demonstrate effective 
laparoscopic renal cooling and ischaemic protection, whilst avoiding the weaknesses associated with 
previous methods, would be of great interest to urological surgeons. 
 
1.6.2 Cryopreservation in renal transplantation 
In heart beating donation, normal perfusion with warm blood is followed immediately by 
cold perfusion before the organs are removed and placed on ice i.e. there is no primary warm   42 
ischaemic period. As cryopreservation greatly attenuates the effects of ischaemia, organs retrieved in 
this way can be assumed to suffer minimal injury (see Fig 1.2). 
 
Figure 1.2 – Typical Core Temperature in a Controlled Heart-Beating donor 
 
Measurement of intra-abdominal organ temperature during retrieval from a Brain-Stem Dead donor. 
Note that organs are well-perfused with warm oxygenated blood until the marked point of in-situ 
cold perfusion and introduction of ice. Relatively rapid cooling is then achieved (Jennings, 2001). 
 
In the case of NHB donation, a primary warm ischaemic period is unavoidable. In this 
situation warm kidneys with high metabolic rates are denied oxygen and metabolic substrates. The 
length of this period and therefore the severity of ischaemic injury resulting injury varies with the 
Maastricht categories.  
NHBD renal transplantation is made possible only because of interventions which ameliorate 
the effects of warm ischaemia. In the controlled situation (cat. III and IV) kidneys may be subjected 
to injury during the period of potential sub-optimal or hypoperfusion known as the ‘agonal time’.   43 
This is defined as the period between withdrawal of life-supporting treatment and cardiac arrest. 
Most centres place a limit on the maximum agonal period accepted. However, the controlled 
situation allows prior mobilisisation of personnel and resource, and following a ‘no touch’ period 
after cardiac standstill, the retrieval team is able to act immediately. Techniques of DBTL femoral 
cannulation (in the ITU setting) and/or rapid laparotomy and aortic cannulation (in theatre), prior to 
cold in-situ perfusion and the introduction of ice to the abdomen, allow rapid establishment of organ 
cryopreservation interventions.  
The uncontrolled (cat. II) NHBD situation requires powerful organ preservation techniques. 
The French have recently instituted an uncontrolled NHBD program with the majority of donors 
subject to a procurement/preservation protocol based on aortic placement of a DBTL catheter 
(Figure 1) and cold in-situ perfusion as soon as possible after declaration of death (Antoine et al., 
2008). The recently established ‘condition T’ protocol in Pittsburgh employs similar techniques 
(International NHBD Meeting, London, May 2008). The European approach to the uncontrolled 
donor was developed through the experiences of groups such as Maastricht (Daemen et al., 1994). 
Newcastle-upon-Tyne has been retrieving kidneys from uncontrolled donors since 1998, using a 
modified Maastricht approach which includes an initial streptokinase flush. Although the protocol 
has been subject to evolution and improvement over time, techniques are focused on the timely 
introduction of cold in-situ perfusion to provide sufficient renal cooling and preservation until the 
donor can be taken to theatre; often as long as two hours after declaration of death (Balupuri et al., 
2000c, Gok et al., 2002d).  
Unfortunately, Newcastle has found that these techniques have a limited effect on core body 
and hence renal temperature. A previous study used an infra-red laser thermometer to measure intra-
abdominal temperature (left lobe of liver surface temperature at laparotomy) on retrieval of category   44 
II kidneys with a mean of 29.5°C after 120 minutes of perfusion (Jennings, 2001) (Figure 1.3). For 
this period renal cells would have remained metabolically active and continued to consume 
significant quantities of ATP. Adequate cooling and reduction of the effects of warm ischaemia 
cannot currently occur until laparotomy is performed and abdominal ice slush introduced. Because 
of the logistical difficulties and legal formalities associated with uncontrolled NHBDs two hours of 
in-situ perfusion may pass before the donor reaches theatre for laparotomy.  
 
Figure 1.3 – Typical Core Temperature in an uncontrolled NHBD. 
 
Measurement of intra-abdominal organ temperature during retrieval from a Category II NHBD. Note 
that effective cooling is not achieved until laparotomy and the introduction of ice, approximately two 
hours after death (Jennings, 2001). 
 
At present, during part of the warm ischaemic period of the NHBD, in-situ perfusion and 
external cooling will improve the level of ischaemic injury. This is achieved by a small cooling 
effect and via the benefits of the preservation solution. However the temperatures achieved suggest   45 
that the increased PNF and DGF rates associated with NHBDs are likely to be related to inadequate 
preservation methods. 
 
1.6.3 Peritoneal Cooling in NHBDs 
The peritoneal cavity is large and easily accessible percutaneously, while the surface area of 
the peritoneum itself is extensive enough to permit effective dialysis. These properties would suggest 
that the peritoneum may offer an excellent route for core body cooling, and indeed the use of 
peritoneal cooling for systemic hypothermia has been described since the 1950s. The technique has 
also been described for cooling in heat stroke and malignant hyperpyrexia (Gjessing et al., 1976) and 
resuscitative hypothermia to limit neurological injury in stroke and cardiac arrest (Horowitz, 1989). 
In contrast, the intra-peritoneal administration of warm fluids is an established method of treating 
severe hypothermia, and can achieve re-warming rates of 5-10°C/hour.  
Peritoneal cooling has been shown to be effective at reducing core temperature in animal 
studies. Xiao et al showed in a canine cardiac arrest model that peritoneal cooling reduced core 
temperature measured in the pulmonary artery by 0.6°C/min, four times the cooling rate achieved by 
surface cooling with ice bags (Xiao et al., 1995). Takahashi et al, using an ex vivo canine model with 
ATP measurements and biochemical markers of ischaemia, demonstrated that peritoneal cooling 
gave equivalent results to cooling by cardiopulmonary bypass, and better results than in-situ 
perfusion alone, in heart, liver and kidney transplantation (Takahashi et al., 1996).  Yadav et al 
compared in situ perfusion alone with a combination of in situ perfusion and peritoneal cooling in a 
porcine model of warm ischaemia, and found the addition of peritoneal cooling to significantly 
reduce renal core temperatures (Yadav et al., 1997).   46 
In Human donors, the Washington Hospital Center group reported data from their Rapid 
Organ Recovery Program (RORP) for uncontrolled DCDs which was implemented in 1994. RORP 
used both intra-vascular cooling and peritoneal cooling with two laparoscopic trocars inserted into 
the lower abdomen with a closed refrigerated circuit of iced normal saline continuously recirculated 
throughout the peritoneal cavity. The fully refined system was reportedly capable of achieving 
peritoneal temperatures of 10°C in 8 minutes, with IVC temperature falling to 15°C in 30 minutes 
and 10°C by 60 minutes (Light et al., 1997, Light et al., 2000a, Light et al., 2000b). However, the 
donors described were younger than commonly seen in Europe, and were mainly trauma victims at 
the MedSTAR trauma unit. Furthermore, no control group approximating the Newcastle / European 
protocols of in-situ cold perfusion alone were described. It is therefore not possible to draw firm 
conclusions regarding any potential benefit over that achieved by the Maastricht approach-based 
protocols.  
 
The aims of this thesis flow from the broad areas covered within this introduction, namely; 
ischaemic injury assessment, laparoscopic renal cryopreservation, and peritoneal cooling for 
NHBDs.   47 
 
 
 
 
 
 
Aims   48 
1.7 Aims 
 
Ischaemic injury Assessment 
To assess the efficacy and potential of ischaemic injury assessment or viability testing within a renal 
Non Heart Beating Donor (NHBD) transplantation program by: 
a) Prospective assessment of the effects of warm ischaemia on retrospectively established measures 
of organ viability; machine perfusion and perfusate enzyme analysis in a large animal model. 
b) Assessment of outcomes of NHBD kidneys with low severity pre-arrest acute renal failure 
selected using machine perfusion viability testing  
c) Assessment of outcomes from dual renal transplantation of ‘marginal kidneys’ selected using 
machine perfusion viability testing 
 
Laparoscopic Renal Cryopreservation 
d) To develop a device for laparoscopic renal cooling 
e) To develop a large animal model for laparoscopic renal cooling 
f) To assess the efficacy of a laparoscopic renal cooling device using transplantation organ viability 
assessment 
 
Peritoneal Cooling 
g) To develop a large animal model of the uncontrolled NHBD for assessment of the efficacy of 
additional peritoneal cooling versus current protocols. 
h) To establish a human trial of uncontrolled NHBD peritoneal cooling. 
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Methods 
 
 
2.1 Organ Recovery Systems Lifeport ® Kidney Transporter 
This is the most commonly used kidney hypothermic machine perfusion device in 
transplantation today. The unit is self-contained within a plastic shell, which incorporates a lockable 
lid (Figure 2.1). 
 
Figure 2.1 
Organ Recovery Systems Inc. Lifeport ® Kidney Transporter 
 
 
 
The kidney is contained within disposable sterile plastic inserts, which include an organ 
cradle and lidded fluid chamber. The insert also incorporates the fluidics system, which involves 
sterile tubing, a filter, and a bubble-trap (Figure 2.2).  
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Figure 2.2 
Lifeport Sterile Insert; Organ Cradle sitting within the Perfusate Fluid Chamber, Fluidics 
System and Sensor Connector. 
 
 
 
 
Once situated within the insert, the renal artery is connected to the perfusion circuit using specialized 
connection devices. Two methods exist; the Sealring and straight cannula (Figure 2.3).  
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Figure 2.3 
Lifeport Components for Connection between Renal Artery and the Machine Perfusion 
Circuit 
 
 
 
 
For Sealring connection an adequate aortic (Carrel) patch is required. This method represents 
the ideal technique for connection to the machine as the renal artery is untouched and hence 
undamaged, with the seal formed at the edges of the patch (which may be used safely as trimming 
invariably occurs prior to transplantation). The Carrel patch is gently passed into the Sealring as 
shown in Figure 2.4. The patch is then carefully positioned so as on hinge-closure the arterial wall of 
the patch is sandwiched circumferentially between the upper and lower seals. The rubber securing 
bands can then be tightened to complete the connection.   53 
 
 
Figure 2.4 
Connection of Lifeport® Sealring to Renal Arterial Aortic Patch 
 
 
 
 
If the patch is absent or too small, a straight cannula may be used by direct placement into 
the arterial lumen, before securing with a tie (Figure 2.5). This method is effective, but risks damage 
to the arterial intima which may necessitate shortening of the artery prior to transplantation. This 
may cause technical difficulties and increases the risk of vascular thrombosis. 
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Figure 2.5 
Connection of Lifeport® Straight Cannula to Renal Artery 
 
 
 
In the case of multiple patches or cut vessels, as a result of non-standard anatomy and 
additional polar renal arteries, combinations of two sealrings and/or straight cannulae may be 
connected using the coupler tubing shown in Figure 2.3. This allows both arterial circulations to be 
perfused on the single circuit. 
The insert’s fluid chamber (inside which sits the cradle and organ) is placed into the ice 
container, so as to surround the chamber with ice to effect cooling. The insert / ice container then fits 
into the Lifeport casing. An electronic link connects the parametric sensors, within the insert fluidics 
system, to the Lifeport displays and computer / memory systems. In addition a flexible portion of the 
insert tubing is designed to fit around a peristaltic pump head (Figure 2.6). Once all of this is in place 
the lid of the perfusate chamber is removed under aseptic conditions, and cold perfusion/preservation 
solution (1L Kidney Preservation Solution, KPS®) is poured, using a no-touch technique, into the 
chamber so as to fill it and surround the kidney. At this point the unit’s power is activated and   55 
instructed to ‘wash’. This activates the roller pump and commences an initial fluidic system prime 
and bubble purge. Fluid is drawn from the bottom of the chamber, through the filter system, into the 
bubble trap, and back to the chamber. Once completed the system is set to ‘prime’, which sends fluid 
from the bubble trap to the perfusion portion of the circuit. This tubing can then be connected to the 
seal ring or straight cannula. On completion of the circuit, the pressure rise is detected by the system 
and the pump stopped. At this point, the operator instructs the Lifeport to ‘perfuse’. The pump is 
activated and will adjust its speed in order to achieve the pressure instructed (usually 30mmHg). 
This pressure drives the preservation solution into the renal artery and the kidney is perfused. The 
solution then leaves the kidney via the renal vein back into the fluid chamber reservoir. 
 
Figure 2.6 
Lifeport® with Sterile Insert installed 
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Machine perfusion at high pressures is potentially damaging. The Lifeport therefore prevents the 
operator from using excessively high pressures (40mmHg max.). As mentioned above, the pump will 
drive fluid until the selected pressure is achieved down-stream. It then stops rotating before 
resuming when the pressure falls below the target.  
Data available to the operator is: flow rate, resistance, pressure setting, perfusate temperature, 
and ice container temperature. These parameters are involved in viability assessment. The flow rate 
is estimated from pump speed, which has been calibrated and set in the factory using different size 
apertures and by measurement of the volume circulating per minute. This is an accepted and accurate 
method, used for flow estimation in all clinical dialysis pump systems.  
 
2.2. Machine Perfusion Viability Testing 
 
2.2.1 Pressure Flow Index 
The protocol is detailed in the Introduction, Chapter 1.5.3.2. 
 
2.2.2 Measurement of Perfusate Glutathione-S-Transferase (GST) 
Total GST (i.e., including alpha-, mu-, pi-, and other GST isoforms) is used for viability 
assessment in Newcastle. The method employed is a GST Colorimetric Activity Assay (Gok et al., 
2003b) and is based upon the GST-catalyzed reaction between glutathione (GSH) and the GST 
substrate, CDNB (1-chloro-2,4-dinitrobenzene, which has the broadest range of isozyme 
detectability). The GST-catalyzed formation of CDNB-GSH produces a dinitrophenyl thioether 
which can be detected by a spectrophotometer at 340 nm. One international unit of GST is defined as 
the amount of enzyme producing 1 mmol of CDNB-GSH conjugate/minute under the conditions of   57 
the assay. All GST assays were kindly performed by the Freeman Hospital department of 
biochemistry under the auspices of Dr. Robert Peaston. 
 
2.3 Microdialysis 
  Microdialysis is a technique to monitor the chemistry of the extracellular space in living 
tissue. When a physiological salt solution is slowly pumped through a microdialysis probe the 
solution equilibrates with the surrounding extracellular tissue fluid. After a period of time it will 
contain a representative proportion of the tissue fluid’s molecules (Figure 2.7). 
Microdialysate is then extracted and can be analysed immediately. This study employs the 
validated markers of glucose, pyruvate, lactate and glycerol for assessment of the degree of renal 
ischaemia and cell injury within a tissue (Keller et al., 2008, Weld et al., 2008). In well-perfused, 
oxygenated renal tissue extra-cellular fluid (ECF) glucose levels will remain within normal levels. 
Glycolysis produces relatively static concentrations of pyruvate, measurable prior to convertion into 
acetyl-CoA which enters the Kreb’s cycle. In ischaemic tissues glucose concentrations fall as 
perfusion decreases and available glucose is exhausted. As the degree or duration of ischaemia 
increases, anaerobic conditions will force the conversion of pyruvate to lactate. Thus in early or 
partial renal ischaemia pyruvate/lactate ratios may reflect aerobic/anaerobic metabolic balance. With 
complete ischaemia of longer durations, only anaerobic metabolic activity is possible due to absolute 
absence of oxygen. Therefore pyruvate levels will fall as cellular glucose is exhausted, and all 
available pyruvate will be converted to lactate. Subsequently, lactate levels will rise, and plateau as 
pyruvate is consumed in an effort to raise ATP.  
Glycerol can be used as a marker of cell injury or death. In this context, the role of glycerol is 
as a major constituent of the plasma membrane (Keller et al., 2008, Weld et al., 2008). As ATP   58 
levels fall the ATPase pump transporters in the cell membrane fail, leading to cellular influx of 
sodium and calcium and efflux of potassium. This results in osmotic cell swelling, loss of plasma 
membrane integrity, glycerol release, and cell death. 
 
Figure 2.7 
Schematic representation of the microdialysis catheter tip. 
 
 
 
The bold red arrow demonstrates the flow of microdialysis fluid inside the central lumen of the 
catheter, before exiting at the tip and passing alongside the semi-permeable membrane to form 
microdialysate (following equilibration with the ECF). The bold blue arrow then indicates passage of 
microdialysate into a collection vial.   59 
2.3.1 CMA 600 Microdialysis Analyzer ® 
The CMA 600 Microdialysis Analyzer is a small clinical chemistry analyzer, designed and 
manufactured by CMA Microdialysis Ltd, Stockholm, Sweden (Figure 2.8). It allows analysis of the 
very small volumes of microdialysate obtained from microdialysis catheters or probes. Reagents are 
available for glucose, lactate, glycerol, urea, pyruvate and glutamate. 
The CMA 600® incorporates a single-beam photometer system for colorimetric 
measurement of the differential optical absorbance of a sample with respect to a reference. The 
sample and the reference are held in a two compartment container. A rotating transport wheel driven 
by a stepping motor is utilized to move the container so as to pass the sample and the reference 
through a light beam in succession. The intensity of the light transmitted through the sample and the 
reference is measured by a photocell. The output from the photocell is fed into an electronic system 
which produces an output signal corresponding to the differential optical absorbance of the sample 
with respect to the reference. This allows for production of a calibrated measurement. 
The sample tray has 9 positions for direct analysis and 24 positions for batch analysis. There 
are positions for four reagents and one calibrator. The CMA 600 needs about 1 µL of sample plus 
the amount required for the different assays. Sample and reagent volumes are controlled by a syringe 
pump equipped with a precision glass syringe of 500 µL. Absorbance measurements are made with 
the single-beam filter photometer described above, equipped with a LED and wavelength filters for 
375 and 546 nm.  
Four different analytes can be measured per sample and data may be displayed as trend 
curves on a computer screen. It is possible to monitor nine catheters or probes simultaneously. The   60 
analysis takes approximately 1.5 minutes per analyte and the results are stored immediately hard 
disk to minimize the risk of data loss.  
 
Figure 2.8 
CMA 600 ® Microdialysis Analyzer 
 
 
 
2.3.2. Assays 
  The CMA microdialysis assays for measurement of biochemical markers of ischaemia utilize 
a final common product; quinonamine is a red / violet coloured molecule which absorbs light at a 
wavelength of 546nm. The CMA 600 is consequently set up to detect absorbance at this wavelength 
allowing quantitative assessment of the proportional analyte sample concentration. 
 
 
2.3.2.1 Lactate 
Microdialysate lactate concentration was determined using a quantitative colorimetric 
method. Lactate is ezymatically oxidized by lactate oxidase (LOD). Hydrogen perosxide is produced   61 
reacts with 4-chlorophenol and 4-aminoantipyrine, catalysed by peroxidase (POD). This produces 
the red-violet coloured quinonamine. The rate of formation of quinonamine is proportional to the 
lactate concentration as measured photometrically by the CMA 600 microdialysis analyzer at a 
wavelength of 546nm (Figure 2.9). 
 
Figure 2.9 
Colorimetric assay for quantitative determination of Lactate concentration 
                                                                LOD 
Lactate   +   O2   +   H2O   →   Pyruvate   +   H2O2 
 
                                                                                                                               POD 
H2O2   +   4-Chlorophenol   +   4-Aminoantipyrine   →   Quinonamine 
        +   2 H20   +   HCl 
 
2.3.2.2 Pyruvate 
Pyruvate is enzymatically oxidized by pyruvate oxidase (PyrOx). The hydrogen peroxide 
formed reacts with 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine 
(TOOS). This reaction is catalysed by peroxidase (POD) and produces quinonamine to allow 
colorimetric measurement of pyruvate concentration. 
 
Figure 2.10 
Colorimetric assay for quantitative determination of Pyruvate concentration 
                                                                                                              PyrOx 
Pyruvate   +   Inorganic Phosphate   +   O2   →   Acetylphosphate   +   CO2                        
                                                                                   +   H2O2  
 
                                                                                                       POD 
H2O2   +   4-Aminoantipyrine   +   TOOS   →   Quinonamine   +   4 H20 
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2.3.2.3 Glucose 
Microdialysate glucose is oxidized by glucose oxidase (GOX). Again hydrogen peroxide is 
formed which reacts with phenol and 4-aminoantipyrine, catalysed by peroxidase, yielding 
quinonamine. 
 
Figure 2.11 
Colorimetric assay for quantitative determination of Glucose concentration 
                  GOX 
Glucose  +  O2  +  H2O   →   Gluconic acid  +  H2O2 
 
                                                                      POD 
2 H2O2  +  4-Aminoantipyrine  +  Phenol   →   Quinonamine  +  4 H2O 
 
 
2.3.2.4 Glycerol 
Microdialysate glycerol is phosphorylated by adenosine triphosphate (ATP) and glycerol kinase 
(GK) to glycerol-3-phosphate, which is subsequently oxidized in the presence of glycerol-3-
phophate oxidase (GPO). Hydrogen peroxide is formed and reacts with 3, 5-dichloro-2-
hydroxybenzene sulphonic acid (DCHBS) and 4-aminoantipyrine. This reaction is catalysed by 
peroxidase and again produces the red-violet quinonamine for colorimetric assessment. 
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Figure 2.12 
Colorimetric assay for quantitative determination of Glycerol concentration 
                                                 GK 
Glycerol   +   ATP   →   Glycerol-3-phosphate   +   ADP 
 
                                                                               GPO 
Glycerol-3-phosphate   +   O2   →   H2O2   +   Dihydroxyacetone phosphate 
 
                                                                                                             POD 
H2O2   +   DCHBS   +   4-Aminoantipyrine   →   2 H2O   +   Quinonamine    
    +   HCl 
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Renal Ischaemic Injury Assessment 
 
3.1 Introduction 
Kidneys transplanted from Non Heart Beating Donors (NHBDs) are generally regarded as 
‘marginal’ grafts due to their association with warm ischaemic injury. The degree of warm 
ischaemia sustained by NHBD grafts is related to the Maastricht criteria, with the most prolonged 
periods occurring in the Category II (uncontrolled) donor. Prolonged warm ischaemia results at best 
in delayed graft function (DGF) and at worst in primary non function (PNF). 
In the UK the demand for kidneys continues unabated, prompting interest in the use of 
‘marginal’ organs in order to increase the donor pool (Gagandeep et al., 2006, Gok et al., 2002b, 
Marks et al., 2006, Whiting et al., 2006). Concerns exist regarding the outcomes of such grafts, with 
several groups reporting increased rates of DGF and PNF (Brook et al., 2003, Cooper et al., 2004, 
Keizer et al., 2005). However, many series have shown encouraging short and medium term 
functional and graft survival outcomes from these donors (Gagandeep et al., 2006, Gok et al., 2002c, 
Marks et al., 2006, Whiting et al., 2006). In addition, it has been shown that transplantation of 
marginal kidneys is associated with a significant survival benefit over maintenance on dialysis (Ojo 
et al., 1999).  
Kidneys from NHBDs have often sustained a significant degree of ischaemic injury. As a 
result it is necessary to assess the extent of this injury prior to transplantation, in order to determine 
whether thresholds of viability have been breached (Balupuri et al., 2000b, Daemen et al., 1995, 
Daemen et al., 1997c, Light, 2000). The Newcastle-upon-Tyne group has shown that viability testing 
can be used to avoid transplantation of organs that are likely to have PNF (Gok et al., 2002b).  
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3.2 Machine Perfusion Viability Assessment 
In Newcastle-upon-Tyne NHBD renal transplantation relies upon a rapid-response retrieval 
team which allows institution of early organ preservation interventions in the controlled and 
uncontrolled donor situation. Following organ retrieval, all NHBD kidneys undergo hypothermic 
machine perfusion which allows assessment of viability. This involves calculation of the Pressure 
Flow Index (PFI), defined as the flow per 100g renal mass divided by the systolic pressure (Balupuri 
et al., 2000b, Gok et al., 2002b), and measurement of perfusate glutathione-S-transferase (GST), an 
enzymatic marker of ischaemic injury (Balupuri et al., 2000b, Daemen et al., 1995, Kievit et al., 
1997, Nyberg et al., 2005).  The Newcastle viability protocol for single NHBD renal transplants 
requires a PFI of ≥0.4 ml/min/100g/mmHg, and a GST level of less than 100 IU/L/100g renal mass 
(Gok et al., 2002b). 
Machine perfusion viability assessment has been in existence for some time. However, 
controversy remains regarding the un-validated nature of current assessment protocols. The research 
described in this chapter seeks to address this controversy; the first study described is the first to 
prospectively assess the Newcastle viability assessment criteria at known warm ischaemic time 
points. This has the potential to confirm or refute a genuine and predictable relationship between 
ischaemic duration and said criteria.  
It shall be seen that with evidence of reliability of current assessment protocols it may be 
possible to utilise this information so as to allow maximisation of organ resources within an active 
renal transplantation program. To achieve this, novel ways of utilising viability assessment 
techniques must be investigated. The second study focuses on the thesis that in terms of organ 
resource management, assessment of potentially damaged organs after retrieval may be more   67 
efficient than flat refusal of donors exhibiting certain negative characteristics (in this case, evidence 
of acute renal failure). 
Another area with the potential to improve donor organ utilisation lies around the 
‘borderline’ viability assessments. An organ which just passes viability assessment and is 
subsequently transplanted may be of similar quality to one which just fails and is subsequently 
discarded. The third study seeks to assess the suitability of dual transplantation for such organs, with 
the aim of increasing the effectiveness of function within recipients and also to decrease the numbers 
of organs discarded. 
 
 
3.3 Viability Testing using Machine Perfusion and Perfusate Enzyme Analysis:  
 
Prospective assessment of the effects of warm ischaemia on retrospectively 
established measures of organ viability  
    
The viability criteria described above were determined retrospectively through analysis of 
outcomes during the evolution of the Newcastle NHBD program (Gok et al., 2002b), much as other 
viability testing centres have established their respective criteria. In a sense all such criteria are 
destined to remain unvalidated, as it would be unethical to transplant organs for which a strong 
suspicion of non-viability exists. In this way it could never be proven that an organ which fails a 
viability assessment would indeed have resulted in PNF if transplanted (Chang, 1995). Although the 
opportunity for true validation of a retrospectively produced viability test is lacking, the case for 
such assessment would be strengthened by demonstration of the relationship between injury and the 
marker seeking to reflect it. Clearly it is impossible to prospectively validate the effect of increasing 
duration of warm ischaemia within a human subject. In order to better elucidate the relationship an 
animal model is required.   68 
3.3.1 Materials and Methods 
Ten anaesthetised juvenile landrace pigs underwent laparoscopic renal mobilisation. In 9 
pigs, one kidney was then subjected to a period of ischaemia of 30, 60 or 90 minutes (giving 3 
kidneys per ischaemic period group). The contra-lateral kidney was used for another study. In the 
10
th pig, both kidneys were used as controls, with normal perfusion prior to retrieval. After rapid 
laparotomy the kidneys were placed on ice and prepared for machine perfusion according to local 
NHBD viability testing protocols (Gok et al., 2002b). PFI and peak GST levels were then 
determined during 4 hours of machine perfusion. 
Statistical analysis was performed using Prism version 4.0 for Windows. Data are expressed 
as mean ± SD. Normality of distribution was confirmed using the D’Agostino and Pearson omnibus 
normality test, prior to unpaired t-test comparison. Non-parametric analysis of continuous data was 
performed using the Mann-Whitney U-test. Categorical variables were compared using Fisher’s 
exact test. Statistical significance was defined as p <0.05. 
 
3.3.2 Results 
Peak PFI (ml.min
-1 100g 
-1 mmHg 
-1) at 4 hours (usually the T3 or T4 value) is the primary 
viability assessment criterion in Newcastle. Mean peak PFI was 1.74 ± 0.16 in the control group 
(normal perfusion prior to retrieval). In the 30 minutes warm ischaemic group mean PFI was similar 
to that seen in controls study groups, 1.33 ± 0.64 (p = 0.456). Mean PFI then decreased significantly 
with increasing ischaemic time versus controls. At 60 minutes it was 0.96 ± 0.30 (p 0.0475), and at 
90 minutes 0.48 ± 0.14 (p 0.0024) (Figure3.1). A linear relationship between PFI and ischaemic 
duration was demonstrated (r
2 = 0.9976) (Appendix 1).  
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Pressure Flow Index (PFI) according to ischaemic duration 
Column demonstrates mean data with error bars denoting SD. In group a (control) n=2 kidneys. In 
groups b-d n = 3. Mann-Whitney U-test statistical comparison between groups is shown. 
 
GST perfusate concentration adjusted for renal mass (IU/L/100g) showed a clear rising trend 
with increasing ischaemia (Figure 3.3), although statistical significance was not achieved. GST was 
not detected in control samples (the assay was not capable of detecting levels <14 IU/L). At 30, 60, 
and 90 minutes, mean peak total GST levels were 31.67 ± 15.37, 38.33 ± 14.50, and 60.00 ± 11.53 
IU/L/100g respectively. 
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Figure 3.3 
Mean peak Glutathione-S-Transferase (GST) concentration per 100g renal mass according to 
ischaemic duration. 
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3.3.3 Discussion 
The Newcastle PFI was seen to accurately reflect in-situ warm ischaemic time and therefore 
the potential degree of ischaemic injury prospectively in a large animal model. This builds on the 
suggestion of previous retrospectively-produced studies that the PFI (Balupuri et al., 2000b, Gok et 
al., 2004b, Gok et al., 2002b), and other protocols which employ resistive indexes (Daemen et al., 
1995, Light, 2000), are able to accurately reflect ischaemic exposure and hence injury.   
Peak GST levels during machine perfusion showed a rising trend with increased ischaemic 
duration, which mirror the retrospective data from earlier work in Maastricht and Newcastle 
(Daemen et al., 1997c, Gok et al., 2003b). 
This study is the first to provide prospective large animal model validation to further support 
the use of combined PFI and GST enzyme viability assessment in NHBD renal transplantation.   71 
 
3.4 Pre-Arrest Acute Renal Failure in NHBD transplantation 
Kidneys from controlled NHBDs (cat. III and IV) are retrieved from donors subject to 
withdrawal of prognostically futile life-support (Gok et al., 2004b). As mentioned elsewhere, they 
generally have a shorter and more predictable warm ischaemic time than those from Maastricht 
category I and II uncontrolled donors, and are thus predisposed to a more favourable outcome after 
transplantation (Daemen et al., 1996, Gok et al., 2002b).  
These donors are usually admitted, treated and investigated in Intensive Care or Therapy 
Units (ITU). Some show evidence of Acute Renal Failure (ARF) through a raised serum creatinine 
(SCr) prior to withdrawal of treatment, without any previous history of renal impairment. This 
apparent deterioration in renal function is invariably caused by the pathological processes 
responsible for situation of medical futility. Many transplant specialists would consider ARF in a 
NHBD as an absolute contraindication for renal transplantation, and hence would halt the donation 
pathway at this point. This view ignores the dynamic nature of renal function in the donor context 
and fails to appreciate the potential reversibility of early ARF. In other words, the threat of 
transplanting damaged organs which might result in PNF is enough to justify abandoning the 
retrieval process. However, the organ viability assessment protocols used in Newcastle-upon-Tyne 
allow testing of the potential reversibility of renal ischaemic injury (Balupuri et al., 2000b, Balupuri 
et al., 2001). Judicious use of such assessments may allow a proportion of individuals with evidence 
of pre-arrest ARF or impairment to be used as renal donors.  
This approach has been followed in Newcastle-upon-Tyne, and in order to address the 
understandable concerns of poor outcome of grafts from category III NHB donors with evidence of 
ARF prior to organ recovery, graft function from these donors was examined, with comparison to   72 
kidneys transplanted from a control group of category III NHBDs with normal pre-arrest renal 
function.  
 
3.4.1 Methods 
All renal transplant recipients from category III donors between 1998 and 2005 were 
identified. Category III NHB referrals come predominantly from the Intensive Care Units (ICU). 
The NHBD retrieval protocol described elsewhere (Gok et al., 2002b) was employed for all donors. 
Viability assessment using PFI machine perfusion (Balupuri et al., 2001), and perfusate GST criteria 
(Daemen et al., 1995, Gok et al., 2003a) was undertaken to determine the suitability of individual 
organs for transplant. 
The RIFLE criteria (acronym indicating Risk of renal dysfunction; Injury to the kidney; 
Failure of kidney function, Loss of kidney function and End-stage kidney disease), can be used to 
classify the severity of acute renal failure (Table 3.1) (Bellomo et al., 2004a, Bellomo et al., 2004b). 
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Table 3.1 
RIFLE Criteria for Acute Renal Failure 
The RIFLE criteria were designed to stratify the severity of renal injury and failure according to 
clinical parameters.  
 
Category  GFR 
Criteria 
Urine Output U/O 
Criteria 
 
 
Risk 
Increased creatinine x1.5 
 or GFR decrease >25% 
UO < 0.5ml/kg/h  
x 6 hrs 
H
i
g
h
 
S
e
n
s
i
t
i
v
i
t
y
 
 
Injury 
 
Increased creatinine x 2  
or GFR decrease >50% 
 
UO < 0.5ml/kg/h  
x 12 hrs 
 
Failure 
Increase creatinine x 3  
or GFR decrease > 75% 
or S-Cr > 4mg/dl 
UO < 0.3ml/kg/h  
x 24 hr or Anuria  
x 12 hrs 
H
i
g
h
 
 
S
p
e
c
i
f
i
c
i
t
y
 
Loss  Persistent ARF = complete loss of kidney function > 4 
weeks 
ESKD  End Stage Kidney Disease (> 3 months) 
 
 
Recipients were divided into study (ARF) and control groups. Allocation to the ARF group 
was made on the basis of changes in serum-creatinine (SCr), as this data is routinely available in 
category III NHBDs. The study therefore included grafts recovered from donors with ARF of any 
severity according to the RIFLE criteria. RIFLE status was determined through comparison of SCr, 
24 hrs before cardiac arrest and immediately prior to withdrawal of treatment. For instance, if SCr 24 
hours prior to cardiac death was 100 mmol.L
-1, but at withdrawal had risen to 200 mmol.L
-1, this 
donor would qualify for the ‘Injury’ RIFLE category, and recipients of organs from such a donor 
would enter the ARF study group. Where no qualifying changes in SCr were identified in the donor, 
recipients entered the control group. In other words, control group donors had no evidence of 
deterioration in renal function prior to cardiac arrest.   74 
The primary endpoints of this study were recipients’ Glomerular Filtration Rate (GFR) 
calculated by Modification of Diet in Renal Disease (MDRD) formula at 3 and 12 months post-
transplant. The secondary endpoints were PNF rate, duration of DGF and rejection rate in the first 
year.  
PNF was defined as permanent loss of graft without evidence of function at any point after 
the transplant, and DGF was defined as graft function sufficiently impaired for the recipient to 
require dialysis. 
Statistical analysis was performed using SPSS version 11.0 for Windows.  Continuous 
variables were compared using Mann Whitney U for non-parametric data.  Categorical variables 
were compared using the chi-square test or Fisher’s exact test if the underlying assumptions of 
asymptotic methods could not be met. .   
 
3.4.2 Results 
From the beginning of phase III of the NHBD program in Newcastle-upon-Tyne (1998) until 
the end of 2005, 49 single kidney recipients from category III NHBDs were identified. As 
mentioned, all kidneys had undergone hypothermic machine perfusion and viability testing prior to 
transplantation.  
9 recipients received kidneys from 5 donors with ARF according to the RIFLE criteria (ARF 
group). In the control group, there were 40 recipients from 25 donors with normal SCr prior to 
cardiac arrest.  
There were no statistically significant differences between the groups for potential 
confounding factors including donor and recipient age and sex, ischaemic times, HLA mismatches, 
incidence of acute rejection, duration of DGF and PNF rates. (Tables 3.2 and 3.3)   75 
Table 3.2 
Statistical Comparison of Donor-related Factors between Study Groups 
 
 
* Mann 
Whitney U 
test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Chi-
square test 
 
 
 
 
HI Head injury, POD Paracetamol over Dose, ICB Intracranial Bleed, SAH Sub-Arachnoid Haemorrhage, MI 
Myocardial Infarction, CVA Cerebrovascular Accident, SDH Sub-Dural Haemorrhage, WIT Warm Ischaemic Time, CIT 
Cold Ischaemic Time 
 
 
  ARF Donor 
N=5 
Normal RF Donor 
N=25 
 
P 
Age Donor (Mean ± SE)  45.2±7.3  38.5±3.6  0.41* 
Sex Donor M:F  3:2  3:2   
Ischaemic times (min)       
1st WIT  19.33±2.6  19.68±1.1  0.94* 
2nd WIT  33.89±4.4  36.53±1.3  0.56* 
CIT  1608±128  1358±52  0.096* 
Total IT  1662±127.2  1414±52  0.095* 
Donor Cause of Death       
HI  1  6   
POD  1  1   
ICB  1  3   
SAH  2  4   
MI    1   
CVA    3   
SDH    3   
Other    4   
HLA Mismatch (Median)       
A  1  1  0.2† 
B  1  1  0.52† 
DR  1  1  0.06† 
S-Cr micromol/l       
24 Hrs pre-arrest  88.0±13.2  79.2±6.16  0.91* 
Pre-arrest  175±35.2  89.8±6.16  0.004*   76 
 
Table 3.3 
Statistical Comparison of Recipient Related Demographic Factors and Outcomes  
 
  ARF Donor  
N=9 
 
 
Normal Renal Function 
Donor 
N=40 
 
P 
Age Recipient (Mean ± SE)  57.1±2.4    49.3±2.0  0.09* 
Sex Recipient M:F  5:3    2:1   
Immediate Function %  75    52.5  0.43† 
DGF %  25    47.5  0.43† 
DGF (days)  18.0 ±1.1    7.5 ±1.7  0.15* 
N = Primary Non-Function  1    0  0.18† 
Rejection %  25    27.5  1† 
eGFR (MDRD)       
3 months  45.36± 6.07  43.78 ±2.23  0.966* 
12 months  42.18± 6.28  44.68± 2.89  0.805* 
 
* Mann Whitney U test 
‡ Fisher Exact test 
 
There was a statistically significant difference in mean pre-arrest SCr of the donor between 
two groups (175 µmol.L
-1 ± 35.2 and 89.8 ± 6.16 for ARF and control groups respectively, p 0.004, 
Mann Whitney U test).  
One transplant in the ARF group resulted in PNF (11.1%). Of the remainder (n=8) the mean 
GFR was 45.36 ml.
 -1 min 
-1 1.73m 
-2 ± 6.07 after 3 months. In the control group after 3 months, the 
mean GFR was 43.78 ± 2.23. Mean GFR after 12 months was 42.18 ± 6.28 and 44.68 ± 2.89 in ARF 
and control groups respectively There was no significant difference between the groups at 3 months 
(p 0.966, Mann Whitney U test) (Figure 3.4), nor at 12 months (p 0.805, Mann Whitney U test) 
(Figure 3.5) 
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Figure 3.4 – Recipients’ GFR at 3 months 
Category III NHBD kidney recipients Glomerular Filtration Rate at 3 months post transplantation; 
Acute renal failure study group versus normal function controls (p 0.966, Mann Whitney U test) 
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Figure 3.5 – Recipients’ GFR at 12 months 
Category III NHBD kidney recipients Glomerular Filtration Rate at 12 months post transplantation 
(p 0.805, Mann Whitney U test). 
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3.4.3 Discussion 
Most clinicians view ARF as a potentially reversible condition. It has multiple aetiologies 
often resulting in renal hypo-perfusion, and in many cases normal renal function resumes following 
adequate resuscitation (Bellomo et al., 2004a, Bellomo et al., 2004b). In NHBDs, kidneys may show 
evidence of ARF prior to arrest, demonstrated by deterioration in SCr. The extent of this damage can 
be assessed by machine perfusion and viability testing, and where the thresholds of viability have 
been breached, the organs are not used. However, organs with pre-arrest evidence of ARF which 
pass viability testing may retain the potential for functional improvement. 
The Newcastle-Upon-Tyne group uses viability testing to avoid transplantation of organs that 
are likely to have PNF (Balupuri et al., 2000c, Balupuri et al., 2001). Machine perfusion has enabled 
selection of viable kidneys based on physical (flow, pressure, resistance, temperature) (Balupuri et 
al., 2001, Light, 2000) and biochemical parameters (glutathione S-transferase) (Daemen et al., 
1997c, Gok et al., 2003a, Kievit et al., 1997). Non-viable kidneys are discarded. 
Of 9 kidneys from donors with pre-arrest evidence of ARF, one resulted in PNF. In this case, 
the donor renal artery was damaged during retrieval preventing machine perfusion and viability 
testing. The second kidney of the pair passed viability testing, and on this basis, both kidneys were 
transplanted. Unfortunately, the un-perfused kidney represents the one case of PNF.  
Those kidneys which passed viability testing and were subsequently transplanted show 
similar results to the Category III donors with normal renal function at the time of donation. The data 
suggests that the Newcastle protocols of ischaemic injury assessment are sufficiently robust as to 
allow determination of the potential reversibility of early renal damage. If other centres pursued a 
similar approach, additional organs from NHB situations (which would at present never progress to   79 
donation) could contribute to the donor pool. In the short term results are certainly favourable. 
However, long term results of using such donor kidneys remains to be determined. 
 
 
3.5 Dual renal transplantation for kidneys from ‘Marginal’ NHBDs 
Several groups have shown that viability testing can be used to avoid transplantation of 
organs that are likely to have PNF (Balupuri et al., 2000b, Daemen et al., 1995, Light, 2000). 
However, in Newcastle-upon-Tyne the parameters assessed in the course of viability testing appear 
to identify a second group of kidneys, which although unsuitable for single transplantation may be 
considered for dual transplantation. The group is best considered as ‘marginal failures’ against 
original viability testing thresholds. The pressure on renal transplant waiting lists is well-emphasised 
in the introduction (section 3.1).These pressures push retrieval centres to seek options for decreasing 
the rate of discard for retrieved kidneys, in order to maximise resources. One obvious group for 
assessment are the ‘marginal failure’ organs, which lie just beyond the accepted thresholds of 
viability. 
An argument could be made that all organs which fail viability testing, even marginally, 
should be discarded without further thought. In this way, recipients are better protected against PNF. 
However, another view is that although kidneys of this group would be unlikely to produce a 
sufficient glomerular filtration rate (GFR) to support the recipient as a solitary transplant, when used 
together as a dual transplant they could potentially produce sufficient renal function for one patient. 
In order to maximise the number of transplants from NHBD retrievals a program of dual 
kidney transplantation was commenced in Newcastle in 2003. The basic parametric viability 
thresholds used are detailed in the Introduction chapter (section 1.5.3) (Balupuri et al., 2000b, Gok et 
al., 2002b). They involve calculation of the Pressure Flow Index (PFI), defined as the flow per 100g   80 
renal mass divided by the systolic pressure, and measurement of perfusate glutathione-S-transferase 
(GST), an enzymatic marker of ischaemic injury. 
The Newcastle viability protocol for single NHBD (or all prior to 2003) renal transplants 
requires a PFI of ≥0.4 ml/min/100g/mmHg, and a GST level of less than 100 IU/L/100g renal mass. 
All organs with a PFI of <0.4 are discarded, as retrospective analysis suggests irreversible injury is 
likely to have occurred beyond this point (Talbot, D. data on file, 2003). However, if the GST 
measurements are above the original threshold for single organ transplantation (or occasionally due 
to other factors such as donor co-morbidity or cold ischaemic time) Newcastle surgeons may opt for 
a dual transplant. 
The majority of the dual transplant organs in this study were selected on the basis of viability 
assessment. Therefore they had invariably breached the viability criteria deemed safe for single 
organ transplantation in our centre. This precluded randomisation of such organs to single 
transplantation in the context of a randomised control trial. Subsequently, in order to determine 
whether the dual transplants achieved appropriate early functional outcomes, a retrospective study 
was performed. 
 
3.5.1 Materials and Methods 
Dual renal transplantation is performed as an ipsilateral procedure in our centre, allowing 
preservation of one iliac fossa for future use as required. In an ipsilateral dual transplant, both 
kidneys from a single donor are implanted into the right iliac fossa with anastomoses to the common 
(right kidney) and external iliac (left kidney) arterial circulations. The result is a “double-decker” 
configuration, with the right kidney above the right (Figure 3.6). The ureters are implanted 
separately as two ureteroneocystostomies. The procedure therefore necessitates a longer ureter for   81 
the cephalad kidney, as this ureter must exceed the length of the caudal kidney, and allow a tension-
free ureteroneocystostomy. 
The Newcastle unit performed its first dual NHBD renal transplant in December 2003. From 
December 2003 - 2007, 23 dual NHBD renal transplants were identified. Using post-transplant 
recipient GFR at 3 and 12 months as primary endpoints, the dual transplant group was compared 
with a series of 115 single NHBD transplants.  Function was assessed using GFR (ml
-1 min
-1 1.73m
-
2), estimated from patient age, sex, ethnicity, serum creatinine, urea, and albumin using the extended 
MDRD formula (Levey et al., 1999). 
Secondary endpoints were incidence of DGF, PNF and organ discard rate. DGF was defined 
as insufficient initial graft function requiring dialysis, and PNF as permanent graft loss without 
evidence of function at any point. 
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Figure 3.6 
Ipsilateral Dual NHBD Renal Transplant following reperfusion and prior to closure in 
Newcastle 
 
 
 
Statistical analysis was performed using Prism version 4.0 for Windows. Data are expressed 
as mean ± SD. Normality of distribution was confirmed using the D’Agostino and Pearson omnibus 
normality test, prior to unpaired t-test comparison. Non-parametric analysis of continuous data was 
performed using the Mann-Whitney U-test. Categorical variables were compared using Fisher’s 
exact test. Statistical significance was defined as p<0.05. 
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3.5.2 Results 
From December 2003 to December 2007 23 dual renal transplants were performed (17 
Category II, 6 Category III). The majority (n=18) were selected using viable PFIs (≥0.4 
ml/min/100g/mmHg) with high GSTs (>100 IU/100g) in both organs. The remainder were selected 
using viable PFIs with high GSTs plus evidence of poor in-situ perfusion (n=1), poor in-situ 
perfusion alone (n=1), donor co-morbidity alone (n=2), and long CIT alone (n=1). The remainder of 
NHBD transplants for the same period; 115 single NHBD transplants (48 Category II, 67 Category 
III, 1998-2006) were identified for comparison. 
The dual group contained a greater proportion of Category II donors compared to the single 
group according to the NHBD Category II: III ratio; 17:6 (n=23) versus 48:67 (n=115) (p 0.009). 
Otherwise the dual and single groups were well-matched with no significant differences found with 
respect to donor and recipient age, ischaemic times, HLA mismatch, CMV mismatch, and recipient 
cardiovascular risk score. (Table 3.4) 
One dual transplant recipient died 8 months post-transplantation with a functioning graft. 
There was no significant difference in rates of PNF between the groups. Two dual transplants 
resulted in PNF (8.7%), compared with 11 single transplants (9.6%;Table 3.5). The incidence of 
DGF in the dual transplant group was 81.0%, significantly higher than in the single group where the 
incidence of DGF was 59.2% (p 0.049). However no difference was found between the dual group 
and the single Category II donor transplants, where DGF incidence was 88.9%. 
Of the 21 functioning dual transplants the mean GFR after 3 months was 46.2 ± 17.3. In the 
single transplant group (n=104) the 3 month mean GFR was 40.7 ± 13.7. In the dual group 16 
recipients have reached 12 months post-transplant. The mean GFR at this point was 44.6 ± 17.2   84 
versus 43.0 ± 15.7 in the single group (n=81). No significant differences in graft function were 
observed at 3 (p 0.21) or 12 months (p 0.72) post-transplant (Table 3.6, Figure 3.7). 
   
Table 3.4 
Dual and Single Groups; Matching for Potential Confounding Factors 
 
  DUAL  
(N=23) 
SINGLE 
(N=115) 
P 
Donor Age (yr)  49.9 +/-11.6  42.3 +/-15.3  NS 
Recipient Age (yr)  52.8 +/-11.4  49.9 +/-13.1  NS 
Ischaemic Times       
  1
o WIT (mins)  26.5 +/-6.7  21.5 +/- 7.3  NS 
  2
o WIT (mins)  33.1 +/-6.1  38.5 +/- 8.0  NS 
  CIT (hr)  21.7 +/- 1.8  23.7 +/- 4.7  NS 
HLA Mismatch (median)       
  A  1  1  NS 
  B  1  1  NS 
  DR  1  1  NS 
Maastricht Cat. II:III  15:8  48:67  0.009 
CMV Mismatch N (%)  4 (23.5%)  13 (11.3%)  NS 
Recipient 
Cardiovascular Score 
(median) 
7  6  NS 
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Table 3.5  
Complications in the Dual Transplant Group 
 
Complication  Number of Cases (%) 
Primary Non-Function  2 (8.7%) 
Delayed Graft Function  17 (81.0%) 
Acute Rejection  6 (28.6%) 
Vascular Thrombosis  0 
Ureteric complications / Urine leak  2 (9.52%) 
Wound dehiscense  1 (4.76%) 
 
Table 3.6 
Early Outcomes in NHBD Dual Transplants   
RECIPIENT  MAASTRICHT 
CATEGORY 
REASON FOR 
DUAL 
PNF  DGF  GFR  
3/12 
GFR 
12/12 
1  II  Long CIT  -  +  45  67 
2  II  High GST  -  +  73  84 
3  III  Poor in-situ perfusion  -  +  24  33 
4  II  High GST  -  -  30  39 
5  II  Diabetic, renal 
impairment 
-  +  20  20 
6  II  High GST  +  NA  -  - 
7  II  High GST  -  +  87  22 
8  II  High GST  -  +  52  48 
9  III  Diabetic, renal 
impairment 
-  +  40  49 
10  II  High GST  -  -  56  52 
11  II  High GST  -  +  49  52 
12  II  Poor in-situ perfusion 
High GST 
-  +  28  41 
13  II  High GST  -  +  47  Died 
14  III  High GST  -  +  27  20 
15  III  High GST  -  +  58  62 
16  II  High GST  -  +  53  41 
17  II  High GST  -  +  40  43 
18  III  High GST  -  +  50  39 
19  II  High GST  -  +  56  - 
20  III  High GST  -  +  41  - 
21  III  High GST  +  NA  -  - 
22  II  High GST  -  -  67  - 
23  III  High GST  -  -  25  - 
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Figure 3.7 
Functional eGFR outcomes in dual and single NHBD grafts at 3 and 12 months post-
transplantation.  
The median, inter-quartile range and spread of the data is presented with un-paired t-test statistical 
significance. 
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The organ discard rate for each year of Newcastle NHBD program is shown in Table 3.7. 
When examining these, it is useful to consider our NHBD program in three eras; 1998-2001 (basic 
protocol) 2001-2003 (introduction of streptokinase flush during in-situ perfusion), and 2004-2006 
(Dual transplantation established). As previously reported, the introduction of streptokinase 
produced a significant reduction in the non-use rate from 49.4  ± 10.0 %to 28.8 ± 2.9% between the 
first and second eras respectively (p 0.0125). The introduction of the dual renal transplantation 
option has also resulted in a reduction in the non-use rate to 19.1 ± 4.3%, although this did not reach 
statistical significance. (Figure 3.8) 
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Table 3.7 
Discard Rates for NHBD Kidneys; 1998-2006 
Discarded kidneys are those which fail viability assessment and are therefore not transplanted 
following retrieval. 
  NHBD 
PROGRAM 
ERA 
CAT. II-IV 
DISCARDS 
(N/TOTAL) 
CAT. II-IV 
DISCARD 
RATE 
(%) 
CATEGORY 
II 
DISCARDS 
(N/TOTAL) 
CATEGORY II 
DISCARD 
RATE 
(%) 
DUAL 
TRANSPLA
NTS 
(N) 
1998  Basic  7/16  43.8  4/10  66.7   0 
1999  Basic  13/32  40.6  9/20  45.0   0 
2000  Basic  19/30  63.3   16/24  66.7   0 
2001  Streptokinase  16/32  50.0   12/18  66.7   0 
2002  Streptokinase  8/26  30.8   7/14  50.0   0 
2003  Streptokinase  8/30  26.7   5/12  41.7   1 
2004  Dual Transplant  9/34  26.5   6/16  37.5   4 
2005  Dual Transplant  5/26  19.2   2/12  16.7   5 
2006  Dual Transplant  3/26  11.5   2/14  14.3   7 
 
 
Figure 3.8 
Percentage Kidney Discard Rate according to NHBD program evolution 
 
Statistical analysis performed using Fisher’s exact test. 
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3.5.3 Discussion 
The concept of ‘nephron dosing’ suggests that for successful transplantation a critical mass 
of renal tissue is required to satisfy the metabolic demands of the recipient (Nicholson et al., 2000).  
It could be argued that organs which have sustained acute or chronic injury may, if transplanted, 
produce less function per unit mass than might otherwise be expected. As the severity of injury 
increases, a point is reached where the use of a single organ graft will result in transplantation of 
insufficient renal mass to support the recipient.  The only option available to increase the mass of 
renal tissue received from such a donor is to transplant both kidneys into a single recipient, 
effectively doubling the ‘nephron dose’. 
Dual renal transplantation has been previously reported for ‘expanded criteria donors’ 
(ECDs) in the USA, with excellent functional recipient outcomes (Alfrey et al., 1997a, Alfrey et al., 
1997b, Lu et al., 2000). Alfrey et al retrospectively reviewed the outcomes of 52 transplants from 
ECD donors which had been turned down by other centres. These included 15 dual transplants. In 
the dual transplants, the majority of which were from donors aged ≥59 years with a GFR <90 ml. 
min
-1 1.73m
-2, the mean sCr at one year was 1.6mg.dl
-1  (141 µmol.l
-1) ± 1.5, compared to 2.8mg.dl
-1  
(248 µmol.l
-1) ± 1.5 in single organ transplants. The authors therefore suggested that organs retrieved 
from ECDs aged ≥59 years, with a GFR <90 ml.min
-1 1.73m
-2 would be best utilised as dual grafts. 
Employing different criteria for age (≥54 years vs. <54 years) the same group reported later 
outcome data confirming the encouraging performance of 121 dual ECD grafts. At one year dual 
graft recipients mean sCr was 1.7 ± 0.7 mg.dl
-1 (150 ± 62 µmol.l
-1) compared with the single organ 
group where sCr was 2.2 ± 1.0 (194 ±88 µmol.l
-1). In a 50 year old Caucasian male, these sCr values 
would represent GFRs of approximately 46 and 34 ml.min
-1 1.73m
-2 in the dual and single groups   89 
respectively. This suggests that both the dual and single ECD transplant groups reported by Alfrey et 
al and Lu et al were providing roughly appropriate levels of recipient renal function. 
ECDs might generally be expected to perform inferiorly to ‘standard criteria donors’ (SCDs) 
on viability assessment, as they have had a greater exposure to chronic disease processes. Indeed, 
when the Dual and Single transplant groups are assessed according to UNOS ECD/SCD status, ECD 
donors can be seen to make up approximately half of the Dual group, compared to less than 20% of 
the Single group. However, early functional graft performance is unaffected by ECD/SCD status, 
with no significant differences observed between the groups. 
 
Table 3.8  
 
Dual and Single Study Groups according to Expanded (ECD) and Standard (SCD) Criteria 
Donor Status; 12 month Functional Outcomes. 
 
 
 
Dual  
ECD 
Single  
ECD 
Dual  
SCD 
Single  
SCD 
Number  
(% study group) 
11 (47.8%)  20 (17.4%)  12 (52.2%)  95 (82.6%) 
GFR  
at 12 months 
41.7 ± 14.0  42.2 ± 11.0  48.3 ±21.2  43.2 ± 16.7 
 
 
A greater proportion of ECDs were present in the Dual group (47.8% vs. 17.4%). No significant 
differences were observed between any of the 4 groups below following unpaired t-test analysis. 
 
Transplanting two kidneys into one recipient which then produce an excellent GFR is a waste 
of resources. In this situation, patients on the waiting list would have been better served by two 
single organ transplants producing two significantly lower, but sufficient and appropriate recipient 
GFRs. Equally, a dual transplant which produces insufficient function or results in PNF is extremely 
unwelcome. However, consideration must be given to any transplant procedure which has the 
potential to provide an appropriate level of recipient renal function, and also may prevent   90 
unnecessary organ non-use following retrieval. Thus the decision to utilise the dual transplant option 
is a crucial one. 
In this series kidneys suitable for dual transplantation have been identified by several factors 
including prolonged cold ischaemic time after non heart beating donation and where donor stable 
renal function was known to be sub-optimal. However, the majority were selected on the basis of 
viability tests, namely a viable PFI combined with high perfusate GST levels. Currently PFI is used 
purely to decide when an organ must be discarded. Examination of the possibility of using different 
PFI thresholds for single and dual organ transplantation is planned. 
In retrospect two pairs of kidneys (Table 3.6, recipients 2 and 7) probably had an insufficient 
flush prior to machine perfusion producing an artificially high GST, and therefore could have been 
transplanted singly. Patient 7 after excellent initial progress developed problems with 
immunosuppressant medication concordance, resulting in deterioration of graft function. 
Outcomes in the single group were broadly in line with previous publications from this group 
(Gok et al., 2002b), and the GFRs resulting from the dual transplants from ‘marginal’ NHBDs 
correlate well with these. The data demonstrates that pairs of NHBD kidneys with individually 
viable PFIs, but high GST levels, may be transplanted together successfully as dual grafts.  Such 
kidneys, which do not satisfy the criteria for single organ transplantation, can then go on to produce 
early recipient renal function statistically comparable to that of their single organ counterparts.  
Therefore, by utilising the factors outlined above to identify NHBD kidneys suitable for dual 
transplantation, unnecessary organ non-use is avoided and organ resources are maximised. Early 
functional outcomes suggest that dual NHBD renal transplants can reliably generate appropriate 
graft function for recipients. 
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3.6 Conclusions 
  The aims of studies detailed in this chapter were designed to assess the three main aspects of 
the current viability assessment debate. The first issue centres on the arguments of validity; an organ 
which fails a viability test is not transplanted, and therefore the opportunity to prove that the correct 
decision was made (PNF of the graft) is lost. This would be possible in an animal model but 
unfortunately was beyond the resources of the investigator. However, with a clear and predictable 
relationship established between the primary criterion (the PFI) and ischaemic duration in porcine 
model, further weight is added to viability assessment argument. 
  When seeking to maximise an organ resource, two further areas for study are suggested; 
contraindications for donation (or a broadening of the donor pool to include more potentially 
marginal grafts) and organs with ‘borderline’ viability assessment profiles. For the former, one 
doubtful exclusion criteria common to many institutions was highlighted for analysis. As discussed, 
the dynamic and often reversible nature of renal injury suggests that blanket contraindications to 
donation resulting from clinical evidence of such injury may be unwise. The second study 
demonstrates more than acceptable outcomes from donors which other centres would have declined. 
The proviso is that such organs are transplanted only where machine perfusion viability assessment 
requirements are met. 
  Organs which fail viability assessment are discarded. This is clearly disastrous for 
transplantation programs and must be minimised where possible. One way to achieve this is by 
ensuring all routes to effective utilisation are explored. The novel technique of dual renal 
transplantation was identified as exhibiting such potential, and the third study describes excellent 
outcomes from organs which would have previously been discarded. Another route to effective   92 
utilisation is the optimisation of the retrieval and organ preservation process. This is addressed later 
in the thesis (Chapters 5 and 6). 
   
  The validation of the Newcastle machine perfusion renal viability assessment protocols with 
clarification and further delineation of the relationships involved, prompted consideration of the use 
of such techniques in the assessment of renal ischaemic injury as it pertains to other areas of local 
research. An opportunity arose to assess the effects of renal cooling, the current mainstay of renal 
preservation, on viability tests. The next chapter focuses on the assessment of the efficacy of a 
laparoscopic renal cooling device, designed to provide ischaemic protection in the context of a 
partial nephrectomy procedure, using the viability assessments described above.   93 
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Laparoscopic Renal Cryopreservation 
 
 
4.1 Introduction 
Renal surgery often necessitates clamping of the renal artery in order to control blood loss 
from what is an extremely vascular organ. Once surgery is completed, and the cut edges of the 
kidney closed, renal arterial supply can be re-established. Unfortunately, this means ischaemic 
exposure for the renal tissue required to regain normal function following completion of surgery. 
Urologists have long followed the rules set down by Wickham in the late 1960s (Wickham et al., 
1967). The most important of which was to limit renal ischaemic to a maximum of 30 minutes. He 
also suggested that organs should be cooled to limit damage. Consequently, accepted urological 
practice requires effective renal cooling during ischaemic periods. Prior to the advent of laparoscopic 
surgical techniques, the generous exposure of operative sites meant introduction of ice could be 
achieved simply and easily. Although this approach was open to complications of total body 
hypothermia, it was successfully employed for many years. 
  The rise of laparoscopic surgery, with general benefits including reduced infection, pain, 
hospital stay etc, has brought new technical challenges in many surgical specialties. One such 
challenge is renal hypothermia for laparoscopic partial nephrectomy. In section 1.6 of the 
Introduction chapter, previous attempts to achieve an effective device are described. The emerging 
picture is one of a ‘work in progress’ with no single method or device proving effective without 
significant flaws in design, issues of technical complexity, or the potential for complications for the 
patient. To this end, the prototype Newcastle-Upon-Tyne laparoscopic renal cooling device was 
produced. 
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4.2 Design of the Laparoscopic Renal Cooling Device 
The laparoscopic kidney cooling device consists of two parts: the laparoscopic cooling bag 
and the cooling circuit. The principle behind the design of the system is to achieve hypothermia in 
the renal tissue by circulating coolant, maintained at a temperature close to 2°C, across the surface of 
the kidney. 
The laparoscopic cooling bag has a two-layer construction. The coolant circulates between 
these layers. The bag incorporates three catheters, two allow coolant inflow and the other outflow. 
The catheters connect directly into the cooling circuit. The cooling bag opens distally with a 
drawstring running around the open edge. Thus, when the drawstring is pulled from the proximal 
end of the device, the bag closes. ‘Manoeuvring tags’ on the open edge of the bag allow easy points 
for laparoscopic grasper application during deployment (Figure 4.1).  Prior to use of the device the 
kidney to be cooled is fully mobilized. The device is then introduced into the abdomen through an 
18mm port. Using graspers on the manoeuvring tags, the open edges of the bag are pulled down over 
the kidney. Once the kidney is positioned inside the bag the drawstring is pulled, allowing the bag to 
be secured around the hilum whilst completely enveloping the kidney. To begin cooling, the bag is 
primed with coolant and the circuit activated (Figures 4.1 and 4.2).   96 
Figure 4.1 
Schematic representation and photograph of the prototype Newcastle-Upon-Tyne 
Laparoscopic Renal Cooling Device 
Catheters are connected to the fluidic cooling circuit, providing both in- and outflow of coolant. 
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Figure 4.2 
Schematic representation of the device in full deployment, with the drawstring secured around 
the renal hilum.  
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Figure 4.3 
Photograph of the device in full deployment, with the drawstring secured around the renal 
hilum.  
 
 
 
 
 
 
 
The cooling circuit consists of a heat exchanger and peristaltic pump (323 U/D pump, 
Watson-Marlow Bredel Pump Ltd, UK). The heat exchanger is constructed from two stainless steel 
coils in series, packed in ice in a thermally insulated container. When in use the circuit is closed and 
a fixed volume of coolant (0.9% saline) is circulated at a constant rate of 250ml.min
-1 controlled by 
the peristaltic pump. Coolant leak can be detected visually or through changes in flow parameters 
within the circuit.   99 
The device is intended as a prototype to achieve proof of concept in a non-recovery animal 
model, and is therefore not sterile. As the device is developed towards human clinical viability, it is 
planned to reduce the calibre to allow use via a standard 10/12mm access port. 
 
 
Figure 4.4 
The laparoscopic renal cooling system incorporating the device, heat exchange tank containing 
ice slush and steel coils, peristaltic pump and tubing. 
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4.3 Evaluation of the ischaemic protection efficacy of the Newcastle 
Laparoscopic Renal Cooling Device using renal transplantation viability 
assessment criteria in a porcine model 
 
The aim of regional renal hypothermia in laparoscopic surgery is to limit ischaemic injury 
and extend safe operating time. A renal cooling device capable of achieving these aims should also 
be capable of demonstrating functional preservation. To date, many studies which have attempted to 
address the issue of renal injury after warm and cold ischaemia in animal models and have employed 
serum creatinine as a surrogate marker of renal function. However it is increasingly acknowledged 
that serum creatinine is not an accurate indicator of renal damage (Webster et al., 2005). 
In a non-recovery animal model it is not possible to demonstrate functional preservation 
directly. However the relationship between renal hypothermia, attenuation of ischaemic injury, and 
the preservation of renal function following reperfusion is universally accepted. Therefore a device 
which can demonstrate both effective renal cooling and attenuation of ischaemic injury should also 
preserve function. 
A reliable model for the assessment of ischaemic injury exists in the field of renal 
transplantation. As described in detail elsewhere, kidneys from NHBDs are expected to sustain a 
significant degree of ischaemic injury prior to organ retrieval. As a result many transplant centres 
require assessment of the extent of this injury prior to transplantation, in order to determine whether 
thresholds of viability have been breached (Daemen et al., 1995, Gok et al., 2002b, Light, 2000). 
Viability testing thus demonstrates a spectrum of ischaemic injury, which varies with increasing 
ischaemic duration and efficacy of organ preservation interventions (chapter 3, section 3.3). These 
techniques, applied to an animal model of laparoscopic renal ischaemia, allow a reliable means of 
assessing the efficacy of a cryopreservation device.   101 
4.3.1 Materials and Methods 
The study was designed to achieve a power of 80%. Using an alpha of 0.02 to detect a 
pressure/flow index difference of 0.75 ml.ml
-1 100g
-1 mmHg
-1, three kidneys in each group produces 
a power of 82.2%. Two kidneys in each group would have produced a power of 62.8%. The 
requirement, therefore, was for 18 study kidneys with the addition of 2 controls. 
In ten anaesthetised juvenile landrace pigs a 10/12mm infra-umbilical laparoscopic port was 
placed using Hassan’s technique prior to formation of pneumo-peritoneum at 12 mmHg.  Two 
further 5mm ports were placed as necessary under vision. Laparoscopic renal mobilisation was then 
achieved bilaterally. Once fully mobilised with adequate control of the renal pedicle, vessel loops 
were passed twice around the renal vessels. Each end of the loop was then passed through a 15cm 
plastic sleeve. The sleeve was positioned such that one end lay in contact with the renal vasculature, 
it then passed through a port wound so as the other end lay externally. By clamping the vessel loop 
within the sleeve the tension applied could be adjusted at will, in order to effect and relieve renal 
ischaemia.  
In the ten pigs, individual kidneys were subjected to periods of renal ischaemia of 30, 60 and 
90 minutes, with or without device in-situ cooling. This produced one control and six study groups. 
In the control group two kidneys were left untouched with normal perfusion prior to retrieval. Each 
study group therefore included three kidneys. The device was introduced via an 18mm port above 
the location of the kidney. With the kidney completely mobilised save the hilum, the open edge of 
the ‘bag’ portion of the device was pulled down over the kidney using graspers. The open edge of 
the bag was then closed and secured around the hilum using the drawstring, so as the cooling 
apparatus completely enveloped the kidney.  Renal parenchymal and cooling circuit temperature 
monitoring was undertaken throughout each trial using thermocouples and recorded using a data   102 
logger (Pico Technology Ltd, UK). Three thermocouples were placed in the heat exchanger to 
measure the temperature of the coolant and two thermocouples were incorporated in the cooling bag 
for monitoring the renal temperature. These thermocouples were specially constructed in the tip of a 
syringe needle and inserted to a fixed depth of 10mm at each pole. The depth of 10mm was chosen 
to allow measurement of parenchymal rather than surface temperature, whilst limiting the risk of 
damaging the collecting system. This depth and position of thermocouple placement reflects 
methods of core renal cooling assessment used previously (Ames et al., 2005, Gill et al., 2003a, 
Herrell et al., 1998, Laven et al., 2007, Weld et al., 2007). Correct placement was monitored 
visually and function assessed prior to cooling; the measured renal parenchymal temperature was 
expected to approximate oesophageal core temperature. 
With the device in place, the vessel loops were then tightened to achieve renal artery 
occlusion and the cooling circuit activated. In order to fully assess the cooling efficacy of the device, 
the circuit was activated for 30 minutes in each case. Where the ischaemic study period exceeded 
this time, the circuit was stopped and re-warm temperature data collected. The cooling device was 
not re-activated beyond the initial 30 minute cool. The warm ischaemic period effected in the contra-
lateral kidney was timed so as the end of both study periods would coincide exactly. At the end of 
the study period rapid laparotomy was performed and the kidneys placed on ice.  
Following retrieval each kidney received an initial flush of approximately 200ml cold 
Marshall’s solution. The renal artery was then cannulated and placed onto Lifeport
® hypothermic 
machine perfusion. Each kidney was then machine perfused with 1L KPS
® solution using local 
NHBD protocols (Balupuri et al., 2000b, Gok et al., 2002b). 
The PFI was calculated after four hours machine perfusion. The PFI is defined as flow per 
100g renal mass divided by the mean systolic pressure of machine perfusion. A 10ml sample of   103 
perfusate was removed after each hour, before immediate snap freezing in liquid nitrogen. This was 
later analysed for GST using a spectrophotometric assay (Balupuri et al., 2000b, Gok et al., 2002b). 
Peak GST during four hours machine perfusion forms the second major viability criteria in 
Newcastle. 
Statistical analysis was performed using Prism version 4.0 for Windows. Data are expressed 
as mean ± SD, unless otherwise stated. Normality of distribution was confirmed using the 
D’Agostino and Pearson omnibus normality test, prior to unpaired t-test comparison. Non-
parametric analysis of continuous data was performed using the Mann-Whitney U-test. Statistical 
significance was defined as p<0.05. 
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4.3.2 Results 
4.3.2.1 Cooling Efficacy 
The mean performance of the device is shown in Table 4.1 and Figure 4.5 (Appendix 2). Core renal 
temperature measurements presented for any given time point are the mean of the two thermocouple 
readings. In Pig 5, data logger malfunction led to presumably erroneous thermocouple readings 
(Figure 4.6). This data was therefore removed from temperature efficacy analysis. However, as the 
measurement reliability improved during the latter portion of the cooling phase, it was noted that 
effective cooling appeared to have occurred. Data from Pig 5 was therefore included in final cooling 
temperature and later viability assessment analysis.  
The best performance of the device achieved a renal parenchymal temperature of 15
 oC in 
11.2 minutes (Pig 4).  
 
Table 4.1 
Temperature Data for the Newcastle Laparoscopic Cooling Device (n=9) 
 
  Renal Parenchymal 
Temperature after 30 
minutes Cooling (
oC) 
Time taken to reach 
15
oC (minutes) 
Re-warm Time    
15-25
oC         
(minutes) 
Mean ± SD  12.86 ± 4.999  21.35 ± 8.420  22.73 ± 6.470 
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Figure 4.5 
Mean performance of the Newcastle Laparoscopic Renal Cooling Device 
Core renal temperature data is presented according to duration of cooling. Error bars denote 
SD. n=9. 
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Figure 3.6 
Individual cooling curves produced using the Laparoscopic Renal cooling Device according to 
study animal.  
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4.3.2.2 Assessment of Ischaemic Injury Severity (Viability Testing). 
4.3.2.2.1 Pressure Flow Index (PFI) 
In all groups PFI decreased significantly with increasing ischaemic time. Cooling was 
associated with a significantly higher PFI for all ischaemic periods (Figure 4.7). In the warm 
ischaemia groups, significant deterioration of PFI compared to controls occurred by 60 minutes; 
mean PFI 0.90 ± 0.52 vs. 1.88 ± 0.357 (p 0.0001). However in the cooled kidneys at 60 minutes 
mean PFI was not significantly different from controls; 1.54 ± 0.633 vs. 1.88 ± 0.357 (p=NS).  
 
Figure 4.7 
Laparoscopic Renal Cooling demonstrates a significant cryopreservation effect 
according to Pressure Flow Index (PFI) Viability Assessment. 
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4.3.2.2.2 Glutathione-S-Transferase (GST) 
Perfusate GST was not detected in the control samples. The assay is unable to detect levels 
<14 IU/L. For each ischaemic period greater mean GST measurements were associated with the 
warm ischaemic groups in comparison with the cooled groups. GST data showed a clear rising trend 
with increasing warm ischaemia, although statistical significance was not achieved (Figure 4.8). In 
the Cooled groups a plateau was reached after 60 min, with the 60 and 90 min groups demonstrating 
similar mean perfusate GST levels (36.0 ± 1.732 vs. 34.0 ± 4.36 IU/L/100g). 
 
 
Figure 4.8 
Laparoscopic Renal Cooling demonstrates a trend suggesting limitation of perfusate 
GST/100g concentration 
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4.3.3 Discussion 
LPN is considered an excellent treatment for T1a renal cell carcinomas. It has also been 
performed without cooling by expert surgeons with excellent results (Gill et al., 2003b). However, 
arguably the worldwide uptake of LPN has been slower than expected because laparoscopic 
urologists, in the early phase of their experience, do not feel confident that they can perform the 
operation safely within the 30 minute accepted limit for warm ischaemia. This study has 
demonstrated that with the use of a laparoscopic cooling device, safe operating times could be 
extended. This might allow more complex partial laparoscopic resections to be performed, and 
training opportunities for future laparoscopic surgeons would be enhanced. 
The Newcastle laparoscopic renal cooling device is based on a non-invasive concept, with 
potential for rapid application, removal, and re-application during laparoscopic renal dissection.  The 
best performance of this prototype device demonstrated an ability to cool a porcine kidney to 15°C 
in just over 11 minutes, which is in line with the requirements of LPN. The mean performance of the 
device was comparable with many previously published techniques, including methods based on 
principles of vascular (Janetschek et al., 2004), ureteral (Crain et al., 2004, Landman et al., 2003), 
and surface cooling (Ames et al., 2005, Gill et al., 2003a, Herrell et al., 1998, Webster et al., 2005, 
Weld et al., 2007). 
Vascular cooling can be achieved through trans-arterial cold perfusion and effective 
performance has been reported using this approach (Janetschek et al., 2004). Despite this, many 
surgeons would prefer alternative techniques due to the unavoidable risks of vascular injury and 
thrombosis, as well as issues of technical complexity.   109 
Ureteral cooling is undertaken by retrograde perfusion with cold saline via a ureteral access 
sheath. This method requires post-operative stenting, and provides less effective cortical cooling 
than surface techniques (Crain et al., 2004, Landman et al., 2003). 
Surface cooling may be achieved in a number of ways; Herrel et al described a renal cooling 
device based on a concept similar to our own. It consisted of a rectangular double-layered plastic 
envelope through which cold fluid was circulated. The kidney to be cooled was placed into the 
envelope via an open side. Data was presented from cooling trials in four pigs. In 3 pigs the device 
was deployed via an open incision, and in one via an 18mm laparoscopic port. This limits 
assessment of the manoeuvrability and ease of application of the Herrel device in a purely 
laparoscopic setting. The Newcastle device possesses practical design advantages. The ‘bag and 
drawstring’ design is likely to allow greater manoeuvrability and ease of deployment within 
confined spaces when compared to a relatively inflexible, rectangular device. The Herrel device 
cooled to 25ºC within 5 minutes (Herrell et al., 1998), which is comparable to the performance of 
the Newcastle device (mean temperature following 5 minutes of cooling 28.04ºC ± 2.23). Pointedly, 
the Herrel device was not developed further.   
More recently, techniques involving placement of ice slush in close proximity to the kidney 
have been employed and demonstrate effective renal cooling (Ames et al., 2005, Gill et al., 2003a, 
Laven et al., 2007), as do irrigation/suction systems using chilled normal saline (Webster et al., 
2005, Weld et al., 2007). The Newcastle device works on similar physical principles, but unlike 
these systems there is no direct contact between the cooling agent and the organ surface. This 
reduces the likelihood of organ surface damage, contamination or excessive cooling. Also the 
potential problems with core temperature reduction associated with irrigation systems are reduced.   110 
The time necessary for cooling forms part of both the ischaemic and operative times, both of 
which must be minimized. In other words, the benefit of cooling must outweigh the effects of an 
increase in the total length of the procedure. If the best 15
oC cooling time of 11.2 minutes can be 
reliably reproduced or improved upon in human studies, LPN could be interrupted, once cortical 
temperature has reached 25
 oC (mean 22.7 minutes in this study), for a short second period of 
cooling prior to completion. This would provide approximately 60 minutes of protected ischaemia 
with 45 minutes available for operating. Given the potential for development and improvement of 
the Newcastle device, this might prove to be a conservative estimation of benefit to both the surgeon 
and the patient. 
Assessment of benefit assumes that cooling and maintaining kidneys between 15 and 25
oC 
provides ischaemic protection and functional preservation. Previous studies have been unable to 
demonstrate this in non-recovery animal models. Furthermore, in expensive and time-consuming 
animal recovery studies it is difficult to directly assess individual renal function and functional 
preservation. Techniques, such as individual renal vein serum creatinine sampling may not 
demonstrate differences between cooled kidneys and those left to the effects of warm ischaemia, 
despite previous demonstration of excellent cooling (Webster et al., 2005). 
The Newcastle renal NHBD program relies on accurate techniques of viability assessment in 
order to identify a spectrum of ischaemic injury. The application of thresholds of viability to 
individual measures of machine perfusion pressure/flow data (PFI) and enzymatic markers of 
ischaemic injury (GST), allow identification of retrieved organs which will not function if 
transplanted (Balupuri et al., 2000b, Gok et al., 2002b). When applied in an animal model of renal 
ischaemia, these viability tests demonstrate a clear laparoscopic cryopreservation effect with use of 
the cooling device.    111 
4.4 Conclusions 
This study has reinforced the efficacy of topical renal cooling in the laparoscopic setting. It is 
the first to use device-assessment techniques capable of accurate quantitative measurement of renal 
tissue injury in a large animal model. The Newcastle cooling device is currently undergoing further 
development to enhance its efficiency.  Availability of such a device would increase the number of 
urologists able to undertake LPN safely, removing the pressure of completing the procedure within 
30 minutes. 
With regard to NHBD renal transplantation, the results of this study are highly relevant to 
both the viability assessment, and organ preservation debates. Further to the degree of validation 
accorded to the Newcastle viability assessment protocols by the studies described in Chapter 3, the 
cooling achieved by the laparoscopic device was uniformly and predictably reflected by viability 
assessment. By demonstrating a clear relationship with effective cryopreservation, as well as the 
relationship with warm ischaemic duration established previously, greater credibility has been added 
to the argument that viability assessment is capable of accurate reflection of renal injury. 
The debate pertaining to NHBD organ preservation is also informed by this study; the PFIs 
achieved (albeit in porcine tissue) in the cooling arm of the study were better than those commonly 
seen in kidneys retrieved from uncontrolled NHBDs (Talbot, 2008, data on file). Effective 
cryopreservation relies on rapid cooling as until sufficiently low temperatures are reached, ischaemic 
damage will continue to be accrued. It is likely that the impressive organ viability suggested by the 
PFIs achieved after 90 minutes of cooled ischaemia can be explained by the relative rapidity of 
cooling, and subsequent maintenance of efficaciously protective core renal temperatures. As 
suggested above, current techniques of cryopreservation for uncontrolled NHBDs do not appear to   112 
be similarly effective. Therefore the focus of the next Chapter is the optimisation of the 
cryopreservation approach to kidney retrieval in the uncontrolled NHBD.   113 
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Transplantation   114 
Peritoneal cooling in NHBD renal transplantation 
 
 
5.1 Introduction 
 
NHBD kidneys are associated with greater exposure to the deleterious effects of ischaemic 
injury compared to conventional Heart-beating (HB) or Living Related Donor (LRD) organs. 
Variations in warm ischaemic duration are classified according to the Maastricht criteria, with the 
longest periods associated with the uncontrolled (category I and II) donor. Prolonged warm 
ischaemia results in the clinical entities of delayed graft function (DGF) and the much-feared 
primary non function (PNF). 
  The inexorable demand for kidneys has continued unabated in Europe and the USA in recent 
years. This has led to the consideration of marginal donor groups in order to increase the donor pool. 
Given the ischaemic challenges outlined above, especially pertaining to uncontrolled NHBDs, many 
have expressed concerns with the outcome potential of such organs (Cooper et al., 2004, Keizer et 
al., 2005). However, there is a considerable body of evidence which would suggest that despite 
increased rates of DGF, following  recovery, NHBD kidneys can go on to function comparably to 
their HB counterparts (Farney et al., 2008, Gagandeep et al., 2006, Gok et al., 2002b, Whiting et al., 
2006). In the case of uncontrolled NHBD renal transplantation specifically, some European countries 
are legally prevented from utilising controlled NHBDs due to issues of treatment withdrawal. Hence 
they must concentrate on uncontrolled donors. However, many are simply mindful of the potential 
numerical superiority of uncontrolled NHBDs over other donor groups.  
Uncontrolled NHBD renal transplantation is made possible only because of interventions 
which ameliorate the effects of warm ischaemia. The French have recently instituted an uncontrolled 
NHBD program (Antoine et al., 2008) with the majority of donors subject to a 
procurement/preservation protocol based on aortic placement of a DBTL catheter and cold in-situ   115 
perfusion as soon as possible after declaration of death. The recently established ‘condition T’ 
protocol in Pittsburgh also employs similar techniques (International NHBD meeting presentation, 
London, May 2008). The European approach to the uncontrolled donor was developed through the 
experiences of groups such as Maastricht (Booster et al., 1993a, Booster et al., 1993b). Newcastle-
upon-Tyne has been retrieving kidneys from uncontrolled (cat. II) donors since 1998, using a 
modified Maastricht approach which includes an initial streptokinase flush (Asher et al., 2004, 
Balupuri et al., 2001, Gok et al., 2003c). Although the protocol has been subject to evolution and 
improvement over time, techniques are focused on the timely introduction of cold in-situ perfusion 
to provide sufficient renal cooling and preservation until the donor can be taken to theatre; often as 
long as two hours after declaration of death. However, in category II donors the mean renal 
temperatures at laparotomy are 29.5
oC (Jennings N, Navarro A, Talbot D. Data on file. 2007). This 
would indicate that significant improvements in cryopreservation may be possible. 
The literature would suggest that techniques of peritoneal cooling have the potential to 
provide sufficient organ cooling to achieve effective cryopreservation (section 1.6.3). In the previous 
chapter we have also seen evidence of renal ischaemic preservation achieved through rapid cooling 
(section 4.3.2.2). However, in order to assess any potential benefit for human uncontrolled NHBD 
programs a porcine model of the uncontrolled NHBD, comparing current in-situ perfusion (ISP) 
techniques with additional peritoneal cooling is required. This study involves a‘human-ready’ 
peritoneal cooling circuit, real-time direct measurement of biochemical markers of ischaemia within 
the kidneys using microdialysis, core renal temperature measurement, and post-retrieval machine 
perfusion viability testing. 
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5.2 Materials and Methods 
10 juvenile landrace pigs were used with two providing pure controls, each subjected to 2 
hours of warm ischaemia. The remainder formed the 2 study groups of 4 pigs each; the In-Situ 
Perfusion (ISP) group modelled our current uncontrolled NHBD protocol (section 1.5). The 
peritoneal cooling group (PC) modelled current protocols with the addition of peritoneal cooling.  
All pigs were anaesthetised prior to laparotomy and renal dissection (Figure 5.1). Two 
thermocouples and one microdialysis catheter were then placed into each kidney (Figure 5.2). In the 
study groups distal aortic cannulation was achieved with a primed and clamped DBTL catheter 
(balloons deflated). A primed and clamped inferior vena cava venting catheter was also placed 
(Figure 5.3). Renal inspection was then carried out to ensure normal perfusion. The abdomen was 
then closed, and baseline microdialysate samples collected. In the PC group a 10/12mm laparoscopic 
port was included in the abdominal closure, as this is the intended method for gaining access to the 
peritoneal cavity in the human donor situation (Figure 5.4).  
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Figure 5.1 
Renal Dissection.  
 
 
Figure 5.2 
Placement of renal monitoring devices. Thermocouples for temperature measurement and 
Microdialysis catheter for biochemical analysis 
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Figure 5.3 
Preparation for in-situ perfusion (ISP) in the operative phase involving distal aortic placement of a 
clamped and primed DBTL catheter. It was ensured that the renal arteries were positioned between 
the two balloons. A venous venting catheter allows outflow of blood/ perfusate when ISP begins. 
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Figure 5.4 
Abdominal closure at completion of the operative phase of the study protocol 
 
Annotated photograph from the peritoneal cooling group, during the warm ischaemic period. 
Included are; the laparoscopic port (for peritoneal access), outflow tubing, primed and clamped in-
situ-perfusion catheters (DBTL and venous vent), thermocouples and microdialysis monitoring 
equipment. 
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The pig was then killed and the kidneys subjected to a 30 minute warm ischaemic period, as 
this is the limit for uncontrolled NHBD warm ischaemic duration in Newcastle. After 30 mins the 
DBTL balloons were inflated to isolate the renal arterial circulation. In-Situ Perfusion was then 
commenced with cold HTK® solution (4
oC). Local NHBD protocol drug doses were adjusted for 
pig weight (streptokinase flush 0.5 million IU, phentolamine 5 mg, heparin 10,000 IU). In the PC 
group only, the cooling circuit was then assembled (Figure 5.5, section 5.2.1) the abdomen filled 
with cold peritoneal dialysis (PD) fluid and the circuit activated. Temperature and microdialysis 
monitoring of the renal tissue occurred throughout the ischaemic period. 
After 2 hours rapid re-laparotomy and kidney retrieval was performed. The kidneys were 
then placed onto ice, given a Hartmann’s fluid flush, before machine perfusion and viability testing. 
 
5.2.1 Peritoneal Cooling Circuit 
Simple thermodynamic estimations suggest the required base load required for effective 
peritoneal cooling is 7.29kW. Packaged air cooled chillers of sufficient power are available 
commercially. Acrol Ltd. UK assisted with the conversion of such a unit to function within the 
peritoneal cooling circuit. In order to accommodate the base load, the flow rate required was in the 
order of 0.1 L.s
-1. An appropriate Watson-Marlow® peristaltic pump was therefore incorporated into 
the system. (Figure 5.6)   121 
Figure 5.5 
Schematic Representation of the Newcastle Peritoneal Cooling Unit 
 
Peritoneal dialysis (PD) fluid is introduced to the peritoneal cavity via the gas inflow on the 
laparoscopic port. A 2 meter length of tubing (8mm) is inserted into the lumen of the laparoscopic 
port and passed down into the pelvis. The free external end was connects to a stainless-steel heat 
exchange coil (Acrol® Engineering, UK). A second 2 meter length of tubing then connects to the 
steel coil. The coil is placed into the heat-exchange tank, and one length of the tubing placed into the 
Watson Marlow® peristaltic pump. The circuit is then primed before completion of the circuit, by 
connection to the gas inflow of the laparoscopic port. On activation of the pump, warm fluid from 
the abdomen passes to the stainless steel coil (immersed in water at 4
oC) where heat exchange 
occurs. The chilled fluid then passes back into the abdomen to effect organ cooling. 
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Figure 5.6 
Newcastle-upon-Tyne Peritoneal Cooling Unit 
Modified Acrol Ltd chilling unit with heat-exchange tank and peristaltic pump. 
 
 
 
 
Peritoneal dialysis (PD) fluid was introduced to the peritoneal cavity via the gas inflow on 
the laparoscopic port. Once the peritoneal cavity had been filled, a 2 meter length of silastic tubing 
(8mm) was inserted into the lumen of the laparoscopic port before being passed down into the 
pelvis. The free external end was then connected to a stainless steel heat exchange coil. Another 2 
metre length of tubing was then connected to the other end of the steel coil. The coil was placed into   123 
the chilling unit’s heat-exchange tank, and one length of the tubing placed into the Watson Marlow® 
peristaltic pump. The pump could then be activated at a slow rate to prime the circuit. Once primed, 
the pump was stopped before completing and closing the circuit by connection of the tubing to the 
gas inflow of the laparoscopic port. During assembly, care was taken to vent air from the system. 
Thus on activation of the pump, warm fluid from the abdomen passes to the stainless steel coil 
(immersed in water at 4
oC) where heat exchange occurs. The chilled fluid then passes back into the 
abdomen to effect organ cooling. 
 
5.2.2 Temperature monitoring 
Type-K thermocouples were mounted at the tip of a 21G needle and placed at a depth of 1cm 
within the renal parenchyma. Thermocouples were connected to a Pico Technology Limited TC-08 
USB® Data Logger, and recorded using Picolog recorder® software. 
 
5.2.3 Microdialysis 
  Microdialysis is a technique to monitor the chemistry of the extracellular space in living 
tissue. Lactate, puruvate, glucose and glycerol are established markers of ischaemia in renal tissue 
(see Chapter 2 section 3.2). Microdialysis was performed using CMA Microdialysis Limited 
equipment; CMA-63® microdialysis catheters with relevant pumps and microvials for dialysate 
collection. Samples were analysed using the CMA-600® Analyser and reagent kit with Labpilot® 
software. Microdialysate samples were collected every 20 minutes. The first (Time 0) sample was 
collected over the 20 minute period prior to death of the animal and the beginning of the warm 
ischaemic period; samples therefore represent baseline values in well-perfused and oxygenated 
tissue.   124 
 
5.2.4 Machine Perfusion and Viability Testing 
In Newcastle NHBD kidneys undergo hypothermic machine perfusion using the Organ 
Recovery Systems Inc. Lifeport® machine, which allows assessment of viability. This involves 
calculation of the Pressure Flow Index (PFI), defined as the flow per 100g renal mass divided by the 
systolic pressure of machine perfusion (see Chapter 2 section 2). PFI is calculated at the start and 
then hourly during the first 4 hours of machine perfusion (T0-T4). PFI will generally rise during the 
first two hours of machine perfusion before reaching a relative plateau or peak. The peak PFI 
(usually T3 or T4) is used to determine viability.  The Newcastle viability protocol for single NHBD 
renal transplants requires a peak PFI of ≥0.4 ml.min
-1 100g
-1 mmHg
-1  (Navarro et al., 2008b). 
 
5.2.5 Statistical Analysis 
Statistical analysis was performed using Prism version 4.0 for Windows. Data are expressed 
as mean ± SD. Normality of distribution was confirmed using the D’Agostino and Pearson omnibus 
normality test, prior to unpaired t-test comparison. Non-parametric analysis of continuous data was 
performed using the Mann-Whitney U-test. Statistical significance was defined as p<0.05.   125 
5.3 Results 
(Appendix 3) 
5.3.1 Renal Cooling 
In the ISP group only 1/4 cases reached a mean renal temperature of 25
oC. In the PC group 
the mean time taken to reach 25
oC was 12.0 ± 4.81 minutes. The final temperature 90 minutes after 
commencing organ preservation interventions was 26.3 ± 1.46
oC in the ISP group versus 16.9 ± 1.17 
oC in the PC group (p 0.0001) (Figure 5.7). 
 
Figure 5.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean Core Renal Temperature 
Mean core renal temperature according to study group; in-situ perfusion (current protocols) versus 
peritoneal cooling (performed in addition to current protocols). Error bars denote SD. 
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5.3.2 Microdialysis – Markers of Ischaemia 
5.3.2.1 Lactate 
  Lactate levels at time 0, representing values associated with well-perfused and oxygenated 
tissue, and at 20 minutes were not significantly different between the control and study groups. In 
the control group (2 hours warm ischaemia) lactate levels were seen to rise to a peak of 8.73 ± 0.26 
mmol.l
-1 by 120 minutes. In the ISP group, a more modest increase in lactate levels of 1.31 to 3.45 
mmol.l
-1 (vs. 1.44 to 5.98 mmol.l
 -1 in the control group) was seen between 20 and 40 minutes 
(preservation interventions were commenced at 30 minutes). Microdialysate lactate reached a 
plateau after 60 minutes, presumably as the kidneys were cooled to effective cryopreservation 
temperatures. The peak level was significantly lower than controls at 6.42 ± 0.28 mmol.l
-1 (p 
0.0004). With the addition of peritoneal cooling the lactate plateau was reached by 40 minutes (mean 
3.75 ± 0.53 mmol.l
-1), with a peak at 120 minutes of 4.04 ± 0.84 mmol.l
-1. This was significantly 
lower than the current protocol ISP group (p 0.0003) (Figure 5.8). 
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Figure 5.8 
 
Mean Microdialysate Lactate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean renal parenchymal dialysate lactate concentrations according to study group. Mean renal 
parenchymal dialysate lactate concentrations (mmol.l
-1) give an indication of ischaemic severity and 
anaerobic metabolism. Time 0 samples represent dialysate collected prior to induction of ischaemia 
i.e. normal perfusion. Error bars denote SD. Statistical differences between peak-lactate 
concentrations in the ISP and PC study groups are also presented.  
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 5.3.2.2 Glycerol 
Microdialysate glycerol data is presented in Figure 5.9. Levels at time 0 and 20 minutes were 
not significantly different between the control and study groups. Significant differences were present 
by 40 minutes. Mean peak glycerol levels at 120 minutes were 1024.0 ± 65.1 µmol.l
-1 in the control 
group versus 555.3 ± 72.3 µmol.l
-1 in the ISP group (Control vs ISP, p 0.0011), and 284.5 ± 45.8 
µmol.l
-1 in the PC group (ISP vs PC, p 0.0008). 
 
Figure 5.9 
 
Mean Microdialysate Glycerol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean renal parenchymal dialysate Glycerol concentrations (µmol/l) as an indicator of severe renal 
cell injury or death. Data presented by control and study groups. Error bars denote SD. Statistical 
differences between peak-glycerol concentrations in the ISP and PC study groups are also presented. 
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5.3.2.3 Pyruvate 
Pyruvate was found to fall to undetectable levels by 80 minutes in all groups. No significant 
differences were seen between the control and study groups. This is most easily demonstrated in 
tabular form (Table 5.1). 
 
Table 5.1 
Mean Microdialysate Pyruvate 
Mean renal parenchymal dialysate Pyruvate concentrations (mmol.l
-1) as an indicator of aerobic 
metabolism. Data presented by control and study group with statistical differences between the ISP 
and PC study groups shown. 
 
Sample Time 
(min) 
Control  ISP  PC  ISP vs. PC 
Significance 
0 
Normal Tissue 
65.0 
± 12.7 
113.3 
± 68.3 
46.4 
± 16.3 
NS 
20  92.5± 20.5  77.5 
± 69.9 
57.6 
± 39.5 
NS 
40  25.5 
± 2.1 
22.5 
± 27.8 
17.4 
± 5.18 
NS 
60  6.0 
± 8.5 
0 
 
0 
 
NS 
80  0 
 
0 
 
0 
 
NS 
100  0 
 
0 
 
0 
 
NS 
120  0 
 
0 
 
0 
 
NS 
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5.3.2.4 Glucose  
Glucose was found to fall with increasing ischaemic duration in all groups. No significant 
differences were seen between the control and study groups. This is most easily demonstrated in 
tabular form (Table 5.2). 
 
Table 5.2 
Mean Microdialysate Glucose 
Mean renal parenchymal dialysate glucose concentrations (mmol.l
-1) are expected to fall with 
deteriorating perfusion. Data presented by control and study group with statistical differences 
between the ISP and PC study groups shown. 
 
Sample Time 
(mins) 
Control  ISP  PC  ISP vs PC 
Significance 
0 
Normal Tissue 
1.67 
± 1.10 
2.73 
± 0.55 
2.25 
 ± 0.95 
NS 
20  2.29 
± 0.89 
3.15 
± 0.26 
1.83 
± 0.6 
NS 
40  1.02 
± 1.26 
1.91 
 ± 0.92 
0.97 
± 0.92 
NS 
60  0.60 
± 0.84 
0.72 
± 0.71 
0.33 
± 0.30 
NS 
80  0.30 
 ± 0.42 
0.28 
 ± 0.48 
0.21 
 ± 0.20 
NS 
100  0.12 
 ± 0.17 
0.19 
± 0.38 
0.30 
± 0.42 
NS 
120 
 
0 
 
0.11 
 ± 0.23 
0.17 
± 0.25 
NS 
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5.3.3 Machine Perfusion Viability Testing 
Perfusion Flow Index (PFI) 
After fours hours of hypothermic machine perfusion the mean peak PFI in the pure control 
group (no preservation) was 0.47 ± 0.16 ml.min
-1100g
-1 mmHg
-1. This was approaching the PFI 
threshold set for human kidney viability of 0.4. In the study groups, the use of current protocol organ 
preservation interventions in the ISP group resulted in a significantly superior mean peak PFI of 1.09 
± 0.13, compared to controls (p 0.0372). An additional and significant cryopreservation benefit was 
associated with the addition of peritoneal cooling to current protocols in the PC group which 
demonstrated a mean peak PFI of 1.63 ± 0.19 (p 0.0147) (Figure 5.10). 
 
Figure 5.10 
Peak Pressure Flow Index (PFI) 
Data according to control and study groups; box and whisker plot to demonstrate mean, SD, and 
spread of the data. The Newcastle-upon-Tyne PFI threshold for viability is shown (≥0.4 ml.min
-1 
100g
-1 mmHg
-1). 
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5.4 Discussion 
Peritoneal cooling has been shown to be effective at reducing core temperature in 
animal studies. Takahashi et al, using an ex vivo canine model with ATP measurements and 
biochemical markers of ischaemia, demonstrated that peritoneal cooling gave equivalent results to 
cooling by cardiopulmonary bypass, and better results than in-situ perfusion alone, in heart, liver and 
kidney transplantation (Takahashi et al., 1996).  Yadav et al compared in situ perfusion alone with a 
combination of in situ perfusion and peritoneal cooling in a porcine model of warm ischaemia, and 
found the addition of peritoneal cooling to significantly reduce renal core temperatures (Yadav et al., 
1997). 
In Human donors, the Washington Hospital Center group reported data from their Rapid 
Organ Recovery Program (RORP) for uncontrolled NHBDs (Light et al., 1997). As discussed in 
chapter 1 section 6.3, these donors were younger than commonly seen in Europe, and were mainly 
trauma victims. Furthermore, no control group approximating European protocols of in-situ cold 
perfusion alone was described. The RORP system was reportedly capable of achieving peritoneal 
temperatures of 10°C in 8 minutes, with IVC temperature falling to 15°C in 30 minutes and 10°C by 
60 minutes (Light et al., 2000a, Light et al., 2000b). 
Despite this, many uncontrolled NHBD retrieval protocols (including some which have been 
very recently implemented) involve techniques of in-situ cold perfusion in the absence of peritoneal 
or other forms of effective supplemental cooling. Indeed the experience in Newcastle-Upon-Tyne is 
that in-situ perfusion alone does not achieve temperatures effective for renal cryopreservation within 
the timeframes we require. The data presented above, supported by the findings of previous studies, 
suggests that with effective supplemental cooling it might be possible to significantly improve 
uncontrolled NHBD cryopreservation in Newcastle, both in terms of the speed and final temperature   133 
of cooling. Centres considering beginning or improving an uncontrolled NHBD retrieval protocol 
based on cryopreservation should consider the inclusion of peritoneal cooling. 
This study has demonstrated a significant core renal temperature cooling benefit with the use 
of a novel ‘human-ready’ peritoneal cooling circuit. Evidence of improved limitation of anaerobic 
metabolic rate and cellular injury are demonstrated by means of renal parenchymal microdialysate 
lactate and glycerol levels respectively. Local NHBD viability testing protocols also demonstrate 
significantly improved parameters of viability which suggests improved protection from ischaemia. 
These findings translate to a potential for reduced rates of ischaemia-related clinical phenomena. In 
reaction to these findings, permissions were sought and granted to employ the peritoneal cooling 
system in uncontrolled NHBD retrieval in the Newcastle General Hospital, Accident and Emergency 
department.   134 
 
 
Chapter 6 
 
Discussion   135 
Discussion 
6.1 Ischaemic injury Assessment 
6.1.1 The Efficacy of NHBD Hypothermic Machine Perfusion Viability Testing 
The NHBD is subject to a spectrum of ischaemic insults. The dichotomy of the controlled 
and uncontrolled NHBD is well described and reflects the large differences in the potential for injury 
seen between these groups. To those centres which confine their programs to controlled donors and 
produce acceptable outcomes for recipients, no clear need for additional assessment of organ quality 
is perceived (Chang, 1995). However, groups retrieving organs from uncontrolled donors with 
greater propensity for injury, have seen first-hand the consequences of a protocol lacking in 
objective viability assessment (Balupuri et al., 2000c). Such an approach also has the potential to 
suppress negative ischemia-related outcomes in controlled donors, by identification of often 
unexpectedly non-viable organs (Daemen et al., 1995, Gok et al., 2004b).  
The first aim of this thesis was to assess the efficacy and potential of ischaemic injury 
assessment or viability testing within a renal NHBD transplantation program, by prospective 
assessment of the effects of warm ischaemia on retrospectively established measures of organ 
viability; machine perfusion and perfusate enzyme analysis in a large animal model. Despite small 
numbers, a clear linear relationship was demonstrated between the major viability criterion in 
Newcastle, the PFI, and increasing ischaemic duration, with kidneys exposed to 90 minutes of warm 
ischaemia demonstrating PFIs approaching human thresholds of non-viability. The linearity of this 
relationship adds weight to the argument that resistance-based machine perfusion indexes, such the 
Newcastle PFI, are indeed capable of accurately reflecting warm ischaemic duration. After all it is 
the duration of warm ischaemia which exposes organs to the injurious processes which ultimately 
result in irreversible damage.    136 
The trends of increasing GST perfusate concentration seen with increasing ischaemic 
duration failed to reach statistical significance. This was possibly due to the main weakness of the 
studies described within this thesis; low numbers. However, with the statistically robust data for PFI 
assessments, it is also possible that the results reflect the weaknesses of GST as a perfusate injury 
marker. GST perfusate concentration is affected by flow (Daemen et al., 1997c, Gok et al., 2003b) 
and hence in very damaged organs the vascular destruction (responsible for poor flows, high 
resistance, and low PFI) results in less GST being washed out into the perfusate; effectively the 
assay will not ‘see’ the GST which remains inside the organ. This could explain the plateau in GST 
levels between 60 and 90 minutes of warm ischaemia. Conversely, situations have been described 
where high GST levels are associated with excellent flows and PFI on machine perfusion. Such 
situations often involve young organs, presumably with a large number of nephrons per unit mass. 
The contribution of this study does not serve to refute prior criticisms of the accuracy of GST 
as an effective indicator of organ viability. The caveats, such as in young donors or low flow 
situations, which experienced clinicians apply to the interpretation of GST levels, highlight the 
weaknesses of the marker and justify its status as a secondary viability criterion (as it is used in 
Newcastle). However, in situations of moderate flow it can provide useful additional information. As 
cell membrane disruption (and inevitable death) is required for GST circulatory release, levels reflect 
the degree of irreversibility of damage; in effect the degree of nephron loss. 
Critics of organ viability assessment have argued that validation of such tests is impossible as 
those organs which fail are not transplanted (Gerstenkorn et al., 2000). Such statements are strictly 
true but not particularly insightful or helpful. Faced with high rates of PNF, the program leader who 
introduces objective viability assessment will consider the tests ‘validated’ if the PNF rate drops 
significantly following introduction. This has been reported by several groups (Balupuri et al.,   137 
2000b, Balupuri et al., 2000c, Daemen et al., 1995, Light, 2000). However, the retrospective manner 
in which such assessment protocols were established remains a continuous point of criticism. This 
study is the first to prospectively demonstrate the capability of hypothermic machine perfusion 
protocols to reflect warm ischaemic duration and hence severity. 
 
6.1.1.1 Weaknesses and Future Research 
The statistical significance achieved in the PFI data refutes any significant type II error. 
However, the study can be criticised in its scope. Insufficient resources were available to allow 
recovery animal work, which might have included a transplantation model. Future studies should 
seek to evaluate whether the viability assessments described translate into the expected outcomes 
following transplantation. It would then be possible to transplant the kidneys which fail to reach 
thresholds set for human viability. In this way, the unethical and impossible validation of human 
viability assessment could be achieved in a porcine model. 
 
 
6.1.2 Viability Assessment to Maximise Organ Resources 
Objective viability assessments possess several advantages over subjective approaches. In the 
Introduction (section 1.3.5) the cautious response of the senior surgeon to bad experiences with PNF 
was described; stringent donor criteria are exerted in order to exclude situations where organ damage 
is more likely. Such approaches are effective in reducing PNF rates, but result in fewer transplants as 
centres decline opportunities to recover organs from sub-optimal donors or donor situations 
(Metcalfe and Nicholson, 2000).  
The inefficiency of subjective NHBD assessments and non-recovery / discard decisions may 
ultimately threaten the continuation of NHBD procurement within a centre. This was seen in   138 
Leicester in the late 1990’s, where a high discard rate combined with a low organ yield attributed to 
‘next of kin’ consent refusals (Elwell et al., 1997) resulted in eventual termination of the program. 
The Newcastle centre had observed dramatic reduction in PNF rates following the introduction of 
objective viability assessment (Balupuri et al., 2000c). However, the discard rate for uncontrolled 
donor kidneys was still as high as 50% in 2000.  
The efficacy of hypothermic machine perfusion viability assessment protocols in the 
limitation of PNF rates is well established (Balupuri et al., 2000b, Daemen et al., 1995, Gok et al., 
2003b, Light, 2000). However, as alluded to above, many deny an important role for such 
assessment in the controlled NHBD. This may be a justifiable position, but it ignores the potential 
‘net-widening’ effect that judicious use of a ‘recover and assess’ approach can have, especially with 
sub-optimal donor situations. The second aim of the thesis set out to determine whether the value of 
objective viability assessment could be demonstrated in one such situation. 
 
6.1.2.1 Transplantation of Cat. III NHBD kidneys with evidence of pre-arrest Acute 
Renal Failure 
Category III NHBDs may exhibit evidence of deterioration of donor renal function prior to 
death. For many centres, this is sufficient to justify declining the opportunity to recover kidneys. 
This was not the approach taken in Newcastle where objective machine perfusion viability 
assessments are relied upon to identify where thresholds of damage have been breached. 
Clinically diagnosed ARF is characterised by deterioration of urine output and the 
accumulation of serum creatinine (SCr). The two are usually co-existent but data regarding SCr is 
more readily recorded and accessible. The RIFLE criteria for ARF (Bellomo et al., 2004a, Bellomo 
et al., 2004b) describes a familiar spectrum of injury as kidneys progressively approach irreversible 
injury and loss of function. The criteria for the ‘Risk’ and ‘Injury’ classifications suggest the   139 
reversible part of this spectrum, but it should be remembered that such classifications would be 
sufficient for many to decline retrieval. 
Examination of the data presented in section 3.4.2 suggests that Newcastle viability protocols 
effectively identify reversible injury situations, which result in acceptable early post-transplant 
function (Navarro et al., 2006a, Sohrabi et al., 2007). By allowing successful transplantation from 
one sub-optimal donor group, the implication is that viability testing may also allow other previously 
ignored donor sources to be considered. For instance, application of similar principles may be of 
interest in previously-well elderly donors. Prior to this, however, it would be wise to examine 
existing data more closely. Although acute injury appears to reflect predictably in Newcastle 
viability criteria, the effect of chronic pathological processes have yet to be established. 
 
6.1.2.2 Dual Renal Transplantation of ‘Marginal Kidneys’ selected using Machine 
Perfusion Viability Testing 
NHBD transplantation is resource intensive and as such a high non-use rate is a cause of 
great concern for NHS programs. The first experimental chapter of this thesis is concerned with 
prospective assessment of the validity of local viability tests and assessment of potential applications 
for donor pool expansion. The third aim concentrates on an intervention aimed to increase the 
efficiency of the Newcastle NHBD program by utilising organs on the thresholds of viability. 
Simple relaxation of previous viability thresholds will clearly reduce non-use rates, but 
equally certain would be increased rates of PNF. Therefore the only way to utilise ‘borderline’ 
organs is with a novel approach. The ideal solution would be to ‘treat’ the ischaemic injury, so 
improving the quality of the kidneys prior to transplantation. This was the aim of the final aspect of   140 
this thesis, namely the optimisation of the cryopreservation approach. However, the very fact that 
kidneys are paired organs suggests a simple solution. 
Newcastle NHBD program leaders were mindful of Professor Nicholson’s concept of 
‘nephron-dosing’ (Nicholson et al., 2000) when assessing the possibility of utilising acutely or 
chronically damaged organs as dual organ grafts. Other centres have used dual transplantation in 
order to allow utilisation of organs from older donors, or from kidneys with a known degree of 
functional impairment (GFR <90) (Alfrey et al., 1997a, Lu et al., 2000). The question for Newcastle 
was exactly how to select which organs to use in this way. The established viability assessment 
thresholds have been shown to produce satisfactory outcomes for single grafts (Gok et al., 2002b) 
and hence this situation was left unchanged. The PFI had proven itself a trusted indicator and as such 
no consideration was given to any form of transplantation from organs failing PFI criteria. The 
deficiencies of GST as an injury marker have been discussed above. However its usefulness in 
moderate flow situations lends itself to selecting moderately damaged organs suitable for dual 
transplantation. In the Newcastle pre-dual transplant era, viability test failures would often 
demonstrate GST levels greater than the threshold of 100 IU.100g
 -1, but with comfortably viable 
PFIs. This suggested that a significant degree of nephron loss may have occurred, but without 
progression to the vascular destruction and total irreversible functional loss associated with a PFI 
fail. 
The third study in this section demonstrated that selection and dual transplantation of organs 
with viable PFIs but high GST levels are capable of providing equivalent early graft function and 
levels of PNF to single NHBD grafts (Navarro et al., 2008b, Navarro et al., 2006b). Furthermore, the 
levels of renal function suggested by the eGFRs achieved in the dual transplantation group were also 
statistically similar to those of the single group. In other words the organs selected for dual   141 
transplantation were shown to produce sufficient function only. Excessively high eGFRs or levels of 
function might suggest that two single transplants could have been successfully performed with the 
paired organs.  This supports the criteria chosen for dual organ selection and, with the resulting low 
levels of organ non-use, represents evidence of maximisation of organ resources. 
With a clearer picture of the benefits of viability assessment and its role in organ resource 
management and optimisation, attention is turned to focus on techniques capable of improving organ 
quality in kidneys exposed to the deleterious effects of ischaemia. 
 
6.2 Novel Techniques for Clinical Renal Cryopreservation and Ischaemic 
Protection 
6.2.1 Laparoscopic Renal Cryopreservation 
The application of efficient cooling techniques to aid ischaemic protection is of relevance to 
many clinical disciplines. The procedure of laparoscopic partial nephrectomy (LPN) is one area 
where a clinical need for organ hypothermia has been identified but as yet no clearly superior 
technique for achieving it has been described. This premise is supported by the multiple reports of 
alternative methods of instituting laparoscopic renal cooling (Gill et al., 2003a, Herrell et al., 1998, 
Janetschek et al., 2004, Laven et al., 2007, Webster et al., 2005, Weld et al., 2007). Furthermore, 
difficulties in assessment of the efficacy of cryopreservation interventions stem from the weaknesses 
of clinical measures of renal function e.g. SCr. Chapter 4 describes the response to three of the 
original aims of the project; to develop a device for laparoscopic renal cooling, to develop a large 
animal model for laparoscopic renal cooling, and to assess the efficacy of a laparoscopic renal 
cooling device using transplantation organ viability assessment.   142 
The prototype device produced was intended for ‘proof of concept’. It therefore cannot be 
said to represent the final solution for laparoscopic renal hypothermia. The production of such a 
device would require significant further engineering and testing before a human-ready product could 
be made available to surgeons. However, the concept of a closed-system for topical cooling by re-
circulation of chilled coolant across the surface of the organ clearly has merit; topical cooling 
ensures tissue invasion is minimised, and the separation of coolant from tissue, by a thin membrane 
of plastic, reduces the potential for contamination whilst allowing effective heat transfer. The 
various advantages over earlier systems have been well discussed in the relevant Chapter’s 
conclusions. 
The prototype device was shown to achieve satisfactory core renal temperature within the 
time-frames required for LPN. Furthermore, these temperatures translated into improved parameters 
of human renal transplantation-derived organ viability assessments when compared to un-cooled 
controls. This was taken as evidence of cryopreservation efficacy. However, although the PFI and 
GST machine perfusion viability tests are arguably reliable indicators of post-transplant (or in this 
context, post-reperfusion) function (Balupuri et al., 2000b, Daemen et al., 1995, Gok et al., 2004b), 
they remain ‘indicators’ only. The only way to truly demonstrate effective cryopreservation would 
be to perform recovery experiments in which LPN is completed with and without cooling, and the 
function of the isolated partially nephrectomised kidney measured directly. This could be achieved 
through a contra-lateral nephrectomy, and serial measurements of GFR using established clinical 
techniques during the recovery period. 
Unfortunately limited resources precluded this comprehensive approach. However the results 
gained are of significant use in suggesting further research, both through the support of further   143 
investment into device development, and in increasing specialty interest in the benefits of this form 
of laparoscopic renal hypothermia through publication (Navarro et al., 2008a). 
 
 
6.2.2 Peritoneal Cooling for Uncontrolled NHBDs 
In many ways the most challenging aspects of the project, and possibly for NHBD 
transplantation itself, lie in the approach to the uncontrolled NHBD. The cryopreservation approach 
in Newcastle is based on techniques of in-situ perfusion and has been shown to yield insufficiently 
low organ temperatures (Jennings, 2001). The project set out to develop a large animal model of the 
uncontrolled NHBD for assessment of the efficacy of additional peritoneal cooling versus current 
protocols, and ultimately to establish a human trial of uncontrolled NHBD peritoneal cooling. 
The results from the porcine model of the uncontrolled NHBD demonstrate clear 
preservation benefits from the application of supplementary peritoneal cooling in addition to current 
in-situ perfusion protocols. Criteria of core renal temperature, the microdialysis ischaemic markers 
of lactate and glycerol, and hypothermic machine perfusion PFI and GST all suggest superior 
limitation of ischaemic injury compared with the current approach. The main strength of the 
conclusions drawn is the striking nature of the differences seen between study groups, and as such 
the feeling within the unit is that all future human donors should undergo supplementary peritoneal 
cooling. However, the results must be seen in the context of the study’s limitations; these shall be 
discussed in more detail 
 
6.2.2.1 Limitations of the Porcine Study of supplementary Peritoneal Cooling 
  The most obvious limitation derives from the small sample size involved. Ten animals were 
suggested by original power calculations to reflect the expected differences in temperature and PFI   144 
achievable by peritoneal cooling. However, the impressive statistical differences reported may be 
viewed sceptically due to the standard errors commonly associated with studies involving small 
numbers. 
  The viability criteria employed throughout the project have been shown to reflect ischaemic 
duration and injury and microdialysis markers of ischemia are well-validated (Keller et al., 2008, 
Weld et al., 2008). They therefore offer a means of assessing the likelihood of post-transplantation 
graft dysfunction. However, arguably the only completely reliable method is to transplant the organs. 
As with the LPN study, limited resources have precluded a transplantation model. Transplantation of 
kidneys preserved by in-situ perfusion ± peritoneal cooling, followed by close assessment of graft 
function, would undeniably be the best way of directly assessing the likely impact of the intervention 
on clinical NHBD transplantation. 
  Further practical points would include the effect of dissection of the kidneys prior to 
induction of preservation interventions. Partial dissection of the kidneys could potentially have 
improved cooling rates by increasing the surface area of kidney in contact with circulating coolant. 
Also, the pigs used were juvenile and as such possessed very little retroperitoneal fat. In 
uncontrolled NHBDs in Newcastle there is often a significant amount of fat present. The insulating 
effect of retroperitoneal peri-nephric fat could affect the efficacy of abdominal cooling, and this 
limits the strength of the study conclusions. 
 
6.3 NHBD Organ Preservation - Directions for the future 
Extracorporeal membrane oxygenation (ECMO) has the ability to provide near normal organ 
perfusion and oxygenation in the absence of cardiopulmonary function. It therefore possesses a 
theoretical advantage over preservation methods based on organ cooling; the organs are maintained   145 
in physiologically near-normal conditions. This would suggest the potential to minimise injury and 
improve the subsequent viability of NHBD kidneys.  
Systems designed to replace heart and lung function by providing a circulatory pump and 
means of oxygenating the blood have been in existence for over 50 years. In 1953 John Gibbon 
Junior invented the first successful heart-lung bypass machine (Gibbon, 1978). The following year, 
Dr Lillehei’s group developed a cross-circulation technique using anesthetized adult volunteers as 
“live cardiopulmonary bypass machines” during the repair of congenital cardiac defects (Warden et 
al., 1954). By 1955, the Mayo Clinic reported improvements to Gibbon's device which they used in 
successful repair of atrial septal defects (Kirklin et al., 1955). With the establishment of 
cardiopulmonary bypass for elective cardiothoracic surgical applications, such techniques were 
adapted for use in paediatric cardiac and respiratory failure. The bubble oxygenator was described in 
this context in the mid-60s (Rashkind et al., 1965) but this was largely to be replaced by the 
membrane oxygenator (Baffes et al., 1970) found in modern systems. The term ECMO was coined 
at around this time, and differs from conventional cardiopulmonary bypass in that it is established 
through peripheral rather than central vascular cannulation. It is also focused on provision of 
oxygenation support over a longer period than associated with bypass. In essence, the aim is to 
support function and therefore aid recovery. Newer systems designed to provide more robust pump 
support, as well as oxygenation are often described as extracorporeal life support (ECLS) systems. 
  ECLS or ECMO devices are designed to perfuse essential organs with oxygenated blood at 
37
oC. The loss of such an environment following death prompts the transplantation clinician to 
instigate interventions intended to limit the injury that follows. ECMO systems in many ways 
approach the ‘ideal’ preservation intervention (at least theoretically); optimal delivery of 
normothermic oxygenated blood can be restored at will, following declaration of death.   146 
   
 
6.3.1 ECMO in Clinical Transplantation 
ECMO techniques have been applied in NHBD transplantation in several centres 
(D'Alessandro et al., 2004, Gravel et al., 2004, Ko et al., 2000, Magliocca et al., 2005). A schematic 
representation of the type of system employed is given in Figure 6.1.  
The Michigan group implemented a controlled NHBD program involving post-mortem 
ECMO in 1999. ECMO cannulae are placed in the femoral artery and vein following consent to 
donate, but prior to withdrawal of support in the ITU. ECMO circulation is initiated immediately 
following declaration of death, eliminating the primary warm ischaemic time. The donor family may 
remain with the donor for a short time before transfer to theatre for organ recovery. 20 renal 
transplants from 13 ECMO-supported donors were performed between 2000 and 2003. One case of 
PNF secondary to surgical complications was reported. In the 19 functioning grafts, 2 (11%) resulted 
in DGF. The authors called for others to consider ECMO as a viable and effective organ preservation 
modality (Gravel et al., 2004). 
 
In the University of Wisconsin, analysis of short-term outcomes from normothermic ECMO 
for NHB donation of abdominal organs was performed in 2005. Between 2000 and 2004, 20 patients 
entered the UW ECMO-supported NHBD protocol. Retrieval was performed in 15 cases; in 3 
controlled NHBD situations the agonal time exceeded the local 60 minute threshold, and in 2 cases 
organs were deemed unsuitable for transplantation. 14 of the 20 original entrants were category II 
donors (70%). In comparison to results prior to the introduction of the ECMO protocol, the authors 
reported an increase in the donor pool of 33% and an increase of 24% in the number of kidneys   147 
transplanted. Only 2 cases of DGF were encountered, with no PNF or deaths. Conclusions were that 
despite early results and small numbers the indications were that the use of ECMO in uncontrolled 
NHBDs could potentially provide outcomes at least comparable to brain-stem dead donors whilst 
increasing the donor pool (Magliocca et al., 2005). 
 
Figure 6.1 
 
Clearly, normothermic oxygenated organ preservation and retrieval systems, using 
techniques of ECMO, have been employed successfully in controlled and uncontrolled NHBD 
situations with excellent outcomes (D'Alessandro et al., 2004, Gravel et al., 2004, Light and Cecka, 
2005, Magliocca et al., 2005). Both the raw numbers, in terms of transplants, and the numbers of 
centres utilising these expensive and complex techniques are currently small. However, the gross 
limitation of the ischaemia-related complications (DGF and PNF) to levels not previously seen in 
NHBD renal transplantation speaks for itself.    148 
The small number of centres with expertise in this area may well be the pioneers of a new 
approach which all will eventually follow. However, for many established centres a change to an 
ECMO approach might be financially and logistically difficult. Such changes also often take time. In 
addition, interest in ECMO is growing in the field of emergency medicine; ECMO has been used 
successfully in the ITU setting for the resuscitation of respiratory arrest in children (Huang et al., 
2008), and also in the Accident and Emergency setting for adult arrests (Chen et al., 2008). This 
introduces a dangerous problem regarding the role of ECMO in potential donor situations. ECMO 
may become increasingly attractive to both resuscitative emergency medicine and transplantation 
doctors alike. If ECMO demonstrates evidence of benefit to patients and improves in or out-of-
hospital arrest survival then it must be implemented. However, this would represent the potential for 
significant difficulties for the donation process; the transition between a situation where ECMO is 
being used as treatment to preserve life, and where the aim is to preserve organs, will be fraught with 
ethical, legal and practical difficulty. At present the resuscitation team may reach a point where all 
feel that further resuscitation is unwarranted, the patient has died, and the decision is made to stop 
resuscitation interventions. At this point, after a no-touch period, separate interventions may be 
implemented to preserve the organs. With ECMO employed both pre- and post-declaration of death, 
the line becomes blurred; effectively the ‘life support’ machine is switched off and then switched 
back on again. It is difficult to predict the general perception or acceptance of this kind of 
eventuality.  
One ethically ameliorating possibility would be to position an occlusive aortic balloon at the 
level of the diaphragm during preservative ECMO. This would prevent re-perfusion of the heart, 
lungs and brain and exclude the possibility of pseudo-resuscitation. However, such an action may   149 
preclude heart or lung retrieval, the concept of which is growing in popularity within the 
cardiothoracic transplant community. 
Perhaps lessons regarding the impact of such dilemmas will be learned from future 
experiences from the French NHBD protocol; although the majority of the uncontrolled French 
donors will be subject to a crypreservation protocol, in the small number of patients for whom 
ECMO resuscitation is instituted and fails, ECMO will be allowed to continue prior to organ 
recovery and transplantation (Antoine et al., 2008). 
 
 
6.3.2 The Current Situation with Uncontrolled NHBD Organ Preservation 
Regardless of the potential of ECMO-based approaches, the majority of transplant centres 
recovering organs from uncontrolled NHBDs continue to use protocols based on concepts of 
cryopreservation, often involving in-situ cold perfusion alone. Although ECMO-based protocols 
have excellent early results, cryopreservation approaches have yielded successful controlled NHBD 
kidney programs in many parts of the world. Furthermore, the deficiencies noted in results from 
uncontrolled NHBD transplantation programs, based on DBTL in-situ perfusion alone, may be 
attributable to the deficiencies in cooling efficacy demonstrated by studies within this thesis. The 
hope is that those centres aiming to optimise a cryopreservation approach will take note of the data 
presented herein and take steps to include techniques of supplementary cooling within their 
protocols.  
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6.4 Preservation for Uncontrolled NHBDs - Future Research 
The final aim of the project was to establish a trial of human peritoneal cooling. The 
Newcastle peritoneal cooling unit described above is in place at Newcastle General Hospital’s 
Accident and Emergency Department, and awaits the next uncontrolled NHBD donor. A 
comprehensive approach to data collection will be applied in these donors; information regarding 
renal surface temperature at laparotomy, machine perfusion viability testing, and all relevant 
outcome data may then be compared to data from phase III transplants, and the unit’s HBD 
outcomes in retrospective comparisons. 
It is arguable that the ‘gold standard’ approach to demonstration of the potential benefit of 
supplementary cooling requires a randomised controlled trial (RCT). The group gave careful 
consideration to this possibility but chose to follow a full-implementation approach for the following 
reason; the demonstration of the benefit of the addition of peritoneal was clear, despite small 
numbers. In terms of cooling efficacy, microdialysis markers of ischaemic severity, and organ 
viability assessment, a significant improvement in preservation was suggested. It was therefore 
decided that to withhold such an intervention for half of the donors presenting to Newcastle A&E 
would be ethically questionable. In this way uncontrolled NHBDs in Newcastle will all benefit from 
an improved cryopreservation protocol. 
 
6.4.1 Optimised Cryopreservation vs. ECMO for NHBDs 
The augmented cryopreservation protocol described herein, including supplementary 
peritoneal cooling must be compared to an ECMO-based approach before firm conclusions can be 
drawn as to the optimal preservation method. It is likely that in order to demonstrate differences in 
efficacy between two fundamentally different approaches, any animal model will need to assess   151 
post-transplantation outcomes. This would require either a recovery transplantation model or a 
transplantation-simulation (possibly using a rig capable of warm oxygenated reperfusion with 
blood), where immediate or DGF can be identified, and renal function assessed through calculation 
of urine output and GFR. 
The clear ‘room for improvement’ for conventional cryopreservation protocols, suggested by 
the parameters of viability seen in the peritoneal cooling arm of the uncontrolled NHBD study, 
might render the negative financial, practical and ethical implications of ECMO-based approaches 
less attractive to many NHBD programs. 
 
6.5 Final Conclusions 
This project has provided additional evidential support for the assessment of NHBD renal 
ischaemic injury using protocols of viability assessment based on hypothermic machine perfusion; a 
predictable relationship between warm ischaemic duration and renal viability criteria has been 
successfully demonstrated in a large animal model, and novel approaches to the use of such 
assessments have been explored in order to maximise organ resource opportunities and utilisation.  
These are important findings which have been received with interest by the transplant community at 
international meetings. However our understanding of the multitudinous factors contributing to renal 
NHBD transplantation success or failure remains incomplete. This is well-illustrated each time a 
transplanted organ which has passed viability assessment fails to function.  
The recently published, large multi-centre European trial of hypothermic machine perfusion 
versus cold storage (Moers et al., 2009) has demonstrated the incontrovertible benefits of the former 
method of renal preservation. In this trial surgeons were blinded to any information regarding 
machine perfusion or perfusate enzyme parameters. In essence all organs were viability assessed in   152 
the sense that both PFI and GST data was collected, but this information was not used to guide 
clinical decisions. Later sub-group analysis in controlled NHBDs suggested that no differences in 
PNF rates existed between organs above or below previously established thresholds of viability. The 
authors have since argued that no NHBD organs should be discarded on the basis of the viability 
assessment protocols described herein. This is not an unreasonable statement, but it must be 
remembered that only controlled NHBDs contributed to the data; these organs are generally found to 
be of acceptable quality and it is rare for PFI and GST parameters to be approaching or below 
viability thresholds. PNF in organs transplanted from these donors is likely to be due to an as yet 
unidentified confounding factor (or factors) not reflected by the established markers. This suggests 
incomplete understanding and the need for further research, but does not render current protocols 
irrelevant. Had the European study included uncontrolled NHBDs, the data within this thesis would 
suggest that with the considerably greater degrees of associated ischaemic injury, Newcastle 
viability assessment protocols may have provided clinically useful information regarding the risk of 
PNF. 
Despite the evidence described for a role for machine perfusion-derived viability assessments 
the emerging picture is one of incompleteness. PFI and GST reflect only donor and initial organ 
preservation factors. Success or failure may also be influenced beyond this point; in recipient 
selection and preparation, the transplantation procedure itself, and in the post-operative period. The 
sheer complexity of renal ischaemia-reperfusion injury coupled with the equally complex effects of 
the surgical stress of transplantation and graft-recipient immunology would suggest that a viability 
assessment taking into account two relatively simple indicators is bound to be of limited accuracy. 
Future research should not aim to replace PFI and GST but instead to establish additional indicators, 
each aimed at reflecting different parts of the processes involved in the progress from organ   153 
preservation to harvest, preservation and optimisation interventions, transplantation and post-
operative management. In this way a more complex, but equally more robust method for accurately 
predicting organ viability may be achieved. 
The project has made an important contribution in the approach to LPN and laparoscopic 
renal hypothermia. The studies involving the ‘Newcastle Laparoscopic Renal Cooling Device’ 
succeeded in achieving proof of concept with demonstration of effective renal cooling and 
preservation. The work has prompted further development of the device with a view to human 
studies in the near future. 
The studies relating to preservation interventions in the porcine model of the uncontrolled 
NHBD have produced striking results. These results strongly suggest that uncontrolled NHBD 
centres employing cold in-situ perfusion approaches to preservation would be wise to consider 
supplementary techniques of organ cooling. Further avenues of research should assess the efficacy of 
peritoneal cooling in human donors, and seek comparison between ISP and ECMO based techniques 
of organ preservation.  
This final study highlights the potential benefit of careful assessment of the efficacy of each 
part of the transplantation process and has suggested a change in practice capable of improving 
hypothermic organ preservation. Here the wider argument mirrors the call for a more comprehensive 
approach to viability assessment. In order to achieve the best possible outcomes from NHBDs, 
similar attention must be paid to every element of the transplantation process.   154 
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Appendix 1 
 
 
Chapter 3 
 
Renal Ischaemic Injury Assessment 
 
 
 
Prospective assessment of the effects of warm ischaemia on retrospectively 
established measures of organ viability 
 
 
Pressure Flow Index (PFI) according to warm ischaemic duration 
Control  30 mins  60 mins  90 mins 
1.63  0.80  0.86  0.64 
1.85  2.04  1.30  0.38 
  1.14  0.72  0.43 
 
 
Peak Glutathione-S-Transferase (GST) concentration per 100g renal mass according to 
ischaemic duration. 
 
30 mins  60 mins  90 mins 
42.  24  59 
39  53  49 
14  38  72 
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Pre-Arrest Acute Renal Failure in NHBD transplantation 
 
 
Recipients’ GFR at 3 months 
 
ARF 
Normal 
Function 
52.8  55 
50.6  46 
79  34 
41  21 
47.1  40 
38.6  41 
33.9  27 
19.9  34 
  28 
  24 
  40 
  43 
  46 
  19 
  34 
  53 
  44 
  53 
  63 
  60 
  74 
  54 
  42 
  59 
  47 
  58 
  38 
  55 
  81 
  50 
  33 
  30 
  41 
  30 
  39 
  46 
  18 
  49 
  57 
  45 
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Recipients’ GFR at 12 months 
 
ARF 
Normal 
Function 
59.7  39 
44  48 
46  36 
54.8  22 
29.68  47 
18.92  43 
  35 
  26 
  33 
  25 
  25 
  19 
  51 
  20 
  35 
  55 
  51 
  49 
  68 
  62 
  75 
  60 
  33 
  62 
  40 
  80 
  43 
  48 
  82 
  57 
  48 
  39 
  22 
  41 
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Dual renal transplantation for kidneys from ‘Marginal’ NHBDs 
 
Dual Group; Donor Demographics for 16 grafts reaching 12 months post transplantation 
 
Age  Weight  Sex  MC  1st WIT 
2nd 
WIT 
Total 
WIT 
CIT 
hrs  A  B  DR 
CMV 
mismatch 
32  64.0  M  2  39  28  67  20  1  1  1  0 
44  88.0  M  2  17  38  55  21  1  2  1  0 
55  75.5  M  3  24  32  56  20  1  1  0  1 
47  81.0  M  3  29  30  59  22  1  2  0  0 
58  63.0  F  2  29  37  66  22  1  1  1  1 
35  88.0  M  2  27  31  58  22  1  1  1  0 
46  93.0  M  2  32  33  65  22  0  0  1  0 
57  71.0  M  2  25  30  55  23  1  1  1  1 
71  64.5  M  4  25  31  56  22  0  1  0  0 
74  62.0  F  2  23  32  55  23  0  0  0  0 
45  69.0  F  2  15  22  37  18  2  1  0  0 
63  53.5  F  2  25  35  60  23  1  1  1  0 
61  66.5  M  2  17  33  50  22  1  1  1  0 
46  54.0  M  3  33  32  65  22  1  1  1  1 
48  61.0  M  3  24  50  74  18  1  1  1  0 
56  73.5  M  2  33  30  63  24  1  1  1  0 
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Single Group; Donor Demographics for 115 single organ NHBD transplants 
 
MC 
Age  Weight 
Se
x  1
st WIT  2ndWIT  Total WIT 
CIT 
hrs  A  B  DR 
CMV 
mismatch 
3 
63.0
0  79  M  20  35  55  28  1  1  1  1 
3 
63.0
0  75  M  20  42  62  21  1  1  1  0 
2 
47.0
0  86  M  31  60  91  27  1  1  0  1 
2 
52.0
0  66  F  27  36  63  21  0  0  0  0 
3 
64.0
0  59  F  21  35  56  18  1  2  1  0 
3 
37.0
0  58  F  20  38  58  22  1  0  0  1 
3 
51.0
0  62  M  31  37  68  37  1  1  1  0 
3 
53.0
0  53  F  20  38  58  18  1  1  1  0 
2 
65.0
0  74  M  15  32  47  24  2  1  0  0 
3 
42.0
0  63  M  15  26  41  26  0  1  0  0 
3 
42.0
0  30  F  15  37  52  33  1  1  1  0 
2 
47.0
0  83  M  26  22  48  19  1  1  2  0 
3 
38.0
0  75  F  31  44  75  20  1  1  1  0 
3 
59.0
0  85  M  30  37  67  29  2  2  0  0 
3 
71.0
0  61  F  18  35  53  25  1  2  0  0 
2 
47.0
0  70  M  24  35  59  27  2  0  0  1 
2 
52.0
0  66  F  17  42  59  32  1  1  0  0 
2 
52.0
0  68  M  20  40  60  28  0  1  0  0 
2 
59.0
0  52  M  25  54  79  23  1  2  1  1 
3 
33.0
0  51  M  20  45  65  22  2  2  0  0 
3 
33.0
0  65  M  20  31  51  24  1  2  2  0 
3 
49.0
0  140  M  25  46  71  22  1  1  1  0 
2 
52.0
0  79  M  34  32  66  30  1  0  1  0 
3 
47.0
0  92  M  16  31  47  24  2  1  1  0 
3 
47.0
0  85  M  16  41  57  27  2  1  1  0 
3  63.0 73  F  20  37  57  22  1  0  1  1   174 
0 
2 
52.0
0  75  M  24  38  62  23  2  0  0  0 
2 
48.0
0  82  M  15  32  47  31  1  2  0  0 
3 
59.0
0  75  M  30  41  71  20  1  2  0  0 
3 
48.0
0  79  M  20  35  55  28  1  2  1  1 
3 
48.0
0  73  F  20  32  52  34  2  1  1  1 
2 
37.0
0  61  F  18  30  48  28  1  2  1  0 
3 
51.0
0  61  M  10  40  50  24  0  0  1  0 
3 
51.0
0  66  F  10  34  44  18  2  1  0  0 
3 
50.0
0  70  M  24  35  59  18  1  0  1  1 
3 
50.0
0  82  M  24  31  55  24  1  0  1  1 
2 
51.0
0  58  F  14  40  54  24  0  1  1  0 
3 
15.0
0  95  M  18  40  58  23  2  1  0  0 
3 
15.0
0  91  M  18  45  63  18  1  0  1  0 
3 
17.0
0  74  M  20  27  47  11  1  2  0  0 
3 
17.0
0  71  F  20  34  54  21  1  1  1  0 
2 
33.0
0  96  M  16  30  46  25  1  1  1  0 
2 
33.0
0  92  M  16  45  61  13  1  1  0  0 
2 
57.0
0  112  M  27  45  72  20  0  1  1  0 
2 
52.0
0  57  F  35  54  89  30  1  2  0  0 
3 
10.0
0  52  M  20  38  58  13  1  1  1  0 
3 
10.0
0  79  M  20  39  59  17  1  1  1  0 
3 
22.0
0  69  M  19  34  53  19  2  2  0  0 
3 
22.0
0  52  F  19  51  70  20  0  1  1  0 
2 
53.0
0  62  M  18  35  53  22  2  2  0  0 
3 
64.0
0  98  M  13  42  55  21  0  2  0  0 
3 
64.0
0  75  F  13  30  43  26  0  1  0  1 
3 
20.0
0  65  M  10  33  43  18  1  2  1  0 
3  20.0 58  F  10  46  56  25  1  0  0  0   175 
0 
3 
40.0
0  54  M  35  92  127  27  1  2  1  0 
3 
40.0
0  53  F  35  32  67  29  1  2  1  0 
2 
46.0
0  68  M  10  40  50  21  2  1  1  0 
2 
46.0
0  91  M  10  49  59  16  2  1  1  0 
2 
43.0
0  55  M  19  45  64  22  1  2  1  0 
2 
43.0
0  58  F  13  37  50  16  1  1  1  0 
3 
24.0
0  66  M  14  38  52  17  1  1  0  1 
3 
24.0
0  89  M  14  33  47  23  2  0  0  1 
2 
55.0
0  56  M  24  45  69  24  1  1  1  0 
3 
34.0
0  46  F  17  30  47  29  1  2  2  0 
3 
34.0
0  93  M  15  22  37  24  2  1  0  0 
2 
53.0
0  50  M  22  43  65  19  2  1  1  0 
2 
51.0
0  73  M  22  50  72  24  2  2  0  0 
3 
20.0
0  89  F  17  53  70  22  2  1  2  1 
3 
20.0
0  104  M  17  69  86  23  2  1  0  1 
3 
57.0
0  83  M  17  40  57  20  1  1  0  0 
3 
57.0
0  83  M  17  40  57  25  1  0  0  0 
3 
20.0
0  60  F  9  38  47  19  2  0  2  0 
3 
20.0
0  55  F  9  30  39  23  2  1  1  0 
3 
36.0
0  66  M  30  35  65  22  1  1  1  0 
2 
61.0
0  53  M  20  30  50  25  1  1  1  1 
3 
50.0
0  77  M  15  36  51  24  1  1  1  0 
2 
43.0
0  83  M  24  29  53  25  0  1  1  1 
2 
59.0
0  68  M  22  31  53  21  2  2  1  0 
3 
54.0
0  80  M  22  16  38  33  1  1  1  0 
2 
43.0
0  90  M  24  37  61  25  0  2  0  0 
3 
26.0
0  56  M  21  28  49  21  1  1  1  1 
3  26.0 73  F  21  31  52  26  1  1  1  1   176 
0 
3 
50.0
0  70  F  17  45  62  24  1  1  1  0 
2 
28.0
0  66  M  16  47  63  31  1  1  0  0 
2 
45.0
0  61  F  18  32  50  26  1  1  1  0 
3 
54.0
0  69  M  15  31  46  24  0  1  1  0 
3 
65.0
0  64  M  21  35  56  35  1  2  1  0 
3 
22.0
0  77  M  21  39  60  30  0  1  1  0 
2 
49.0
0  75  M  35  35  70  24  0  0  0  1 
2 
49.0
0  95  M  35  41  76  25  0  0  0  1 
2 
38.0
0  86  M  14  52  66  20  1  1  1  0 
2 
52.0
0  81  F  39  49  88  24  0  1  1  0 
2 
38.0
0  74  F  20  47  67  25  1  1  1  0 
3 
22.0
0  52  F  18  39  57  23  0  1  1  0 
3 
50.0
0  59  M  15  42  57  19  1  1  1  0 
3 
22.0
0  75  M  17  37  54  23  2  1  0  0 
3 
57.0
0  75  M  27  40  67  21  0  1  1  0 
3 
38.0
0  59  M  10  29  39  14  1  1  0  0 
2 
45.0
0  72  M  33  33  66  14  1  1  1  0 
2 
54.0
0  80  M  18  60  78  24  1  1  1  0 
2  1.00  81  M  30  42  72  27  2  1  0  0 
2 
39.0
0  76  M  20  40  60  19  2  2  1  0 
2 
42.0
0  60  F  15  21  36  21  1  1  1  0 
2 
61.0
0  70  F  12  50  62  20  1  1  1  0 
3 
57.0
0  66  M  15  30  45  19  0  2  0  0 
2 
54.0
0  86  M  40  34  74  26  1  1  1  0 
3 
34.0
0  60  F  18  35  53  16  1  2  1  1 
2 
54.0
0  70  M  40  36  76  21  1  2  1  0 
3 
28.0
0  72  M  18  29  47  31  2  2  1  0 
2 
28.0
0  64  F  18  32  50  23  2  2  0  0   177 
2 
57.0
0  77  M  34  38  72  28  1  1  0  0 
2 
28.0
0  62  M  30  34  64  27  1  1  1  0 
2 
58.0
0  61  M  19  29  48  27  1  1  0  0 
3 
16.0
0  82  F  32  41  73  19  1  1  1  0 
3 
16.0
0  56  F  32  43  75  26  1  0  0  0 
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Functional GFR outcomes in dual and single NHBD grafts at 3 and 12 months post-
transplantation.  
 
 
Single 
3/12 
Dual 
3/12 
Single  
1 year 
Dual 
1 year 
39.02  45  16.11  67 
31.32  73  33.18  84 
16.93  24  45.61  33 
29.94  30  26.11  39 
47.11  20  47.31  20 
31.61  87  33.36  21.8 
19.4  52  45.86  48.1 
36.24  40  32.43  49.3 
43.46  56.2  39.75  52 
38.14  48.7  23.7  52.1 
48.27  28.2  19.31  41 
33.01  47.1  40.71  20.5 
41.21  26.6  80.66  62.3 
24.59  58.4  50.09  41 
23.96  53.3  57.33  42.8 
37.91  40.2  47.46  39.4 
73.03  50.1  51.88   
64.29  56.3  15.43   
41.32  41  18.68   
36.69  67.4  39.21   
8.76  25.4  78.09   
61.73    38.1   
9.07    52.53   
21.26    27.56   
45.66    46.4   
53.14    28.18   
31.18    22.67   
46.6    32.85   
26.9    29.44   
30.11    50.46   
33.89    40.64   
26.3    40.94   
45.77    48.07   
30.84    34.85   
27.26    17.13   
43.79    41.3   
45.74    22.22   
30.69    43.03   
41.08    44.88   
39.75    51.63   
20.22    19.71   
32.93    72.92     179 
17.13    52.67   
38.70    53.33   
30.24    31.80   
37.76    69.83   
32.52    57.06   
44.16    46.99   
43.21    55.89   
57.11    51.17   
30.00    69.8   
39.21    41.06   
34.67    40.46   
32.21    63.61   
55.34    29.65   
49.31    58.32   
48.45    48.69   
31.62    61.65   
57.58    48.33   
49.36    63.25   
45.52    40.85   
54.71    60.21   
46.66    33.91   
60.93    77.1   
52.75    62.8   
42.64    22.78   
60.43    33.89   
31.53    69.21   
39.43    49.53   
51.11    56.19   
33.02    35.1   
60.84    19.87   
55.31    49.82   
60.31    26.1   
47.13    25.28   
54.69    35.88   
42.81    25.83   
76.07    35.83   
61.25    44.15   
21.80    40.46   
29.17    49.44   
64.24       
53.77       
53.55       
34.45       
19.27       
57.68       
34.91       
41.18       
45.15       
24.28       
27.95         180 
42.12       
56.55       
47.51       
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Appendix 2 
 
Chapter 4 
 
Laparoscopic Renal Cryopreservation 
 
 
Evaluation of the ischaemic protection efficacy of the Newcastle Laparoscopic Renal 
Cooling Device using renal transplantation viability assessment criteria in a porcine 
model 
 
 
Schedule of Ischaemic Times 
. 
 
 
PIG  COOLED KIDNEY (mins)  WARM KIDNEY (mins) 
1  60  30 
2  30  Control – not clamped 
3  60  90 
4  90  60 
5  60  60 
6  30  30 
7  30  30 
8  90  90 
9  90  90 
10  Control – not clamped  60 
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Cooling Efficacy over 30 minutes 
 
Pig 10   Control + warm organ 
Pig 5    Thermocouple malfunction 
 
Time 
minutes  PIG 1  PIG 2  PIG 3  PIG 4  PIG 5  PIG 6  PIG 7  PIG 8  PIG 9 
0.1  30.06  36.53  38.06  36.06  Excluded  34.4  35.66  33.68  36 
2.5  29.75  32.48  34.93  30.84  Excluded  31.48  32.31  31.33  30.8 
5  29.16  29.41  30.77  23.73  Excluded  27.93  27.25  28.02  27.6 
7.5  28.8  26.49  27.01  19.23  Excluded  24.42  22.56  24.49  25 
10  28.29  23.93  24.78  16.31  Excluded  21.16  18.39  21.23  20.8 
12.5  28.65  21.7  23.39  14.04  Excluded  18.66  15.36  18.66  18.3 
15  24.26  20.08  22.02  12.28  Excluded  16.85  12.98  16.71  15.8 
17.5  21.07  18.86  21.1  11.69  Excluded  15.47  11.01  14.93  14.4 
20  19.63  17.35  19.9  10.54  Excluded  14.38  9.47  13.59  13.3 
22.5  17.69  16.08  18.77  9.45  Excluded  13.5  8.12  12.48  12.3 
25  16.6  15.04  17.55  8.94  Excluded  12.57  7.07  11.65  10.9 
27.5  15.36  14.41  16.67  8.55  Excluded  12.14  6.27  10.81  10 
30  13.77  14.16  16.01  7.96  18.59  11.99  5.42  10.15  9.9 
 
 
Individual temperature data, including re-warm for total ischaemic periods exceeding 
30 minutes cooling. (Pig 5 excluded – thermocouple malfunction) 
 
Time 
minutes  Pig 1  Pig 3  Pig 4  Pig 8  Pig 9 
0  30.17  38.6  36.06  33.68  36 
5  29.16  30.77  23.73  28.02  27.6 
10  26.29  24.78  16.31  21.23  20.8 
15  24.04  22.02  12.28  16.71  15.8 
20  19.36  19.9  10.54  13.59  13.3 
25  16.6  17.55  8.94  11.65  10.9 
30  14.32  16.01  7.96  10.15  9.9 
35  20.38  18.05  10.18  9.54  10.18 
40  24.22  20.96  14.77  11.58  12.24 
45  28.8  23.61  19.29  14.32  15.1 
50  32.6  25.64  22.67  16.92  17.06 
55  34.57  27.46  24.8  19.14  19.57 
60  33.53  28.6  26.62  21.23  21.89 
65      28.13  23.14  24.14 
70      29.32  24.4  15.31 
75      30.4  25.68  26.48 
80      31.33  26.76  27.16 
85      32.15  27.68  28.34 
90      32.8  28.62  29.91 
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Pressure Flow Index (PFI) after Four Hours Machine Perfusion according to Duration 
of Warm or Cooled Ischaemia 
Control 
30 
minutes 
warm 
30 
minutes 
cooled 
60 
minutes 
warm 
60 
minutes 
cooled 
90 
minutes 
warm 
90 
minutes 
cooled 
1.85  0.8  1.41  0.68  1.35  0.64  1.01 
1.9  2.02  2.46  1.3  1.03  0.35  1.34 
  1.14  1.39  0.72  2.25  0.43  1.06 
 
 
 
Laparoscopic Renal Cooling demonstrates a trend suggesting limitation of perfusate 
GST/100g concentration 
30 minutes 
warm 
30 minutes 
cooled 
60 minutes 
warm 
60 minutes 
cooled 
90 minutes 
warm 
90 minutes 
cooled 
42  44  24  34  59  29 
39  10  53  37  49  37 
14  20  38  37  72  36 
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Appendix 3 
 
Chapter 5 
 
Peritoneal Cooling in NHBDs 
 
 
Core Renal Temperature 
 
In-Situ Perfusion only group 
(Temperatures 
oC) 
 
Time 
minutes  PIG A  PIG B  PIG C  PIG D 
0  38.62  39.06  38.54  38.11 
5  38.6  39.22  38.52  38.07 
10  38.58  39.33  38.28  38.02 
15  38.52  39.41  38.09  37.82 
20  38.49  39.43  37.96  37.71 
25  38.4  39.47  37.87  37.68 
30  38.29  36.98  37.82  37.67 
35  38.23  32.55  37.75  37.46 
40  38.13  29.49  37.33  35.8 
50  37.97  27.18  35.23  33.66 
55  37.68  26.43  33.98  32.56 
60  37.05  25.81  32.81  31.45 
65  36.2  25.36  31.69  30.41 
68  35.58  25.48  31.06  29.83 
70  35.04  25.21  30.55  29.36 
75  34.09  26.39  29.66  28.56 
80  33.09  27.15  28.73  28 
85  32.15  27.71  28.09  28.43 
90  31.29  27.36  27.65  28.66 
95  30.5  26.33  27.3  28.71 
100  29.72  23.92  27  28.7 
105  29.08  23.13  26.71  28.46 
110  28.54  24  26.39  28.12 
115  28.06  24.38  26.07  27.43 
120  27.88  24.66  25.63  27.16 
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Peritoneal Cooling group 
Temperatures 
oC 
 
Time 
minutes  PIG D  PIG E  PIG F  PIG G 
0  39.59  44.7  39.55  40.97 
5  39.59  44.65  39.51  40.66 
10  39.58  44.64  39.47  40.39 
15  39.51  44.33  39.34  40.17 
20  39.42  44.14  39.41  40.36 
25  39.31  43.99  39.44  40.49 
30  39.21  44.23  39.62  40.19 
35  38.83  30.99  30.69  39.91 
40  26.22  23.16  25.07  32.73 
45  23.98  22.86  23.09  28.2 
50  22.25  22.34  20.24  23.95 
55  20.63  22.06  19.96  20.86 
60  19.39  20.58  19.1  18.23 
65  20.12  19.95  18.34  17.57 
70  20.21  18.59  17.5  17.85 
75  20.7  16.99  17.05  17.9 
80  20.77  16.39  16.27  18.08 
85  19.91  16.06  16.18  18.78 
90  19.93  15.7  16.86  17.85 
95  19  15.25  17.18  16.98 
100  18.9  15.91  16.88  17.6 
105  18.76  15.2  16.37  17.72 
110  17.9  14.99  16.88  18.26 
115  17.29  15.11  16.84  18.31 
120  17.06  15.5  16.7  18.34 
 
 
 
Microdialysis – Markers of Ischaemia 
 
Lactate 
(mmol/l) 
 
Control organs – normal perfusion 
 
Time 
minutes 
Control 
1 
Control 
2 
0  1.09  0.48 
20  1.05  1.82 
40  5.13  6.82 
60  7.59  7.68 
80  8.79  8.13 
100  8.66  8.49 
120  8.91  8.55 
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Lactate 
In-situ perfusion group 
 
Time 
minutes  ISP A  ISP B  ISP C  ISP D 
0  0.88  0.67  0.99  0.78 
20  1.34  1.17  1.44  1.29 
40  3.4  3.33  3.68  3.49 
60  6.44  6.34  6  5.94 
80  6.29  6.01  6.19  6.38 
100  6.64  6.11  6.24  6.67 
120  6.1  5.99  6.21  6.6 
 
 
Lactate 
Peritoneal Cooling group 
 
Time 
minutes  PC A  PC B  PC C  PC D 
0  0.41  0.68  0.8  0.61 
20  1.04  1.23  1.51  1.12 
40  4.31  3.91  3.04  3.74 
60  4.82  3.88  3.14  3.81 
80  4.64  3.84  2.99  3.67 
100  5.2  3.85  3.21  3.9 
120  4.6  3.8  3.15  3.58 
 
 
Pyruvate 
µmol/l 
 
Control group 
 
Time 
minutes 
Control 
1 
Control 
2 
0  74  56 
20  78  107 
40  24  27 
60  0  12 
80  0  0 
100  0  0 
120  0  0 
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Pyruvate 
In-situ perfusion group 
 
Time 
minutes  ISP A  ISP B  ISP C  ISP D 
0  46  68  134  197 
20  34  29  68  179 
40  15  0  12  63 
60  0  0  0  0 
80  0  0  0  0 
100  0  0  0  0 
120  0  0  0  0 
 
 
Pyruvate 
Peritoneal cooling group 
 
Time 
minutes  PC a  PC B  PC C  PC D 
0  36  23  61  57 
20  63  29  31  124 
40  20  16  14  25 
60  0  0  0  0 
80  0  0  0  0 
100  0  0  0  0 
120  0  0  0  0 
 
 
Glucose 
(mmol/l) 
 
Control group 
 
Time 
minutes 
Control 
1 
Control 
2 
0  2.43  0.91 
20  2.92  1.66 
40  1.91  0.13 
60  1.19  0 
80  0.6  0 
100  0.24  0 
120  0  0 
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Glucose 
In-situ perfusion group 
 
Time 
minutes  ISP A  ISP B  ISP C  ISP D 
0  2.61  3.47  2.16  2.67 
20  3.07  3.53  3.01  2.99 
40  1.15  3.15  2.04  1.29 
60  0.89  1.64  0  0.35 
80  0.14  0.99  0  0 
100  0  0.76  0  0 
120  0  0.45  0  0 
 
 
Glucose 
Peritoneal Cooling group 
 
Time 
minutes  PC A  PC B  PC C  PC D 
0  1.23  1.29  3.31  2.5 
20  0.76  2.13  2.11  2.05 
40  0.13  2.51  1.03  0.77 
60  0  0.51  0.71  0.34 
80  0.14  0.5  0.1  0.33 
100  0.13  0.4  0  0.99 
120  0  0.54  0  0.31 
 
 
 
Glycerol 
(µmol/l) 
 
Control group 
 
Time 
minutes 
Control 
1 
Control 
2 
0  79  65 
20  106  171 
40  446  350 
60  729  712 
80  922  870 
100  1070  978 
120  1027  1021 
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Glycerol 
In-situ perfusion group 
 
Time 
minutes  ISP A  ISP B  ISP C  ISP D 
0  43  57  61  51 
20  120  115  138  128 
40  393  364  401  351 
60  410  380  489  399 
80  492  459  543  487 
100  536  463  628  594 
120  540  459  633  587 
 
 
Glycerol 
Peritoneal cooling group 
 
Time 
minutes  PC A  PC B  PC C  PC D 
0  41  38  51  42 
20  104  111  112  99 
40  179  187  132  168 
60  279  264  198  256 
80  270  298  202  264 
100  319  297  213  279 
120  333  301  224  280 
 
 
 
Machine Perfusion 
 
Perfusion Flow Index 
(ml/min/100g/1.73m
2) 
 
Controls  ISP  PC 
0.58  1.02  1.88 
0.36  0.76  1.58 
  1.26  1.64 
  1.31  1.41 
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